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ABSTRACT OF DISSERTATION

THE ROLE OF THE ACE2/ANG-(1-7)/MASR AXIS IN THE DEVELOPMENT
OF OBESITY-HYPERTENSION IN MALE AND FEMALE MICE
Obesity is strongly associated with hypertension and cardiovascular
diseases. An activated renin-angiotensin system (RAS) has long been suggested
as a critical contributor to elevated blood pressure with obesity. Angiotensin II
(AngII), the main effector of an activated RAS, can be catabolized by
angiotensin-converting enzyme 2 (ACE2) to form angiotensin-(1-7) (Ang-(1-7)),
which, acting through the mas receptor (MasR), has been shown to oppose the
effects of an activated RAS. Therefore, further understanding of the mechanisms
of this counter-regulatory arm, called the ACE2/Ang-(1-7)/MasR axis, may lead to
new therapies for obesity-induced hypertension. Previously, we demonstrated
that differences in the regulation of ACE2 in a tissue-specific manner contribute
to sexual dimorphism of diet-induced obesity-hypertension in mice. Whereas
male mice fed a high fat (HF) diet developed hypertension, HF-fed female mice
were protected from obesity-hypertension, and this was associated with
increased activity of ACE2 in adipose tissue of females. Both upregulation of
adipose ACE2 and protection against obesity-hypertension were lost when
females were ovariectomized (OVX). We hypothesized that estrogen-mediated
increases in adipose ACE2 reduce the AngII/Ang-(1-7) peptide balance and
protect females from obesity-hypertension. To test this hypothesis, we first
determined if estrogen restores protection of Ovx female mice from obesityhypertension, and therapeutically protects male mice from obesity-hypertension.
We demonstrated that estrogen administration to Ovx HF-fed females activates
adipose ACE2, reduces plasma Ang II concentrations, and decreases blood
pressure in wildtype, but not of ACE2-deficient obese females. In contrast,
estrogen administration to HF-fed male mice had no on the development of
obesity-hypertension, regardless of genotype. These results demonstrate that
estrogen protects female mice from obesity-hypertension through an ACE2dependent mechanism. Next we defined the role of MasR deficiency on the
development of obesity-hypertension in male and female mice. In HF-fed MasRdeficient female mice, diastolic blood pressure (DBP) was significantly elevated
compared to LF-fed controls, suggesting that protection from obesity-

hypertension was abolished by MasR deficiency. In contrast, HF-fed male mice
with MasR deficiency exhibited reduced blood pressure compared to wildtype
controls which was associated with reduced cardiac function. Overall, these
studies indicate that the ACE2/Ang-(1-7)/MasR axis plays an important role in
sexual dimorphism of obesity-hypertension, and in the regulation of cardiac
function. Moreover, these studies suggest that the effects of this counterregulatory arm of the RAS may be sex-specific.
Keywords: Obesity-hypertension, angiotensin-converting enzyme 2, Angiotensin(1-7), Mas receptor, cardiac function, sex differences
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Section I. BACKGROUND
1.1 Obesity
Obesity, a medical condition characterized by excess body fat mass
accumulation, is recognized as a common risk factor for various diseases.
Clinically, obesity is defined by a body mass index (BMI, weight in kg/height in
m2) ≥ 30 (NHLBI, 1998, Table 1.1) and can be further evaluated in terms of body
fat distribution via waist-hip ratio (Table 1.2) and by the presence of
cardiovascular risk factors. In an individual, obesity is a result of positive energy
imbalance; a combination of excessive energy intake and lack of physical activity
in most cases. Limited cases can be attributed to genetic and environmental
factors. In addition, an increased obesity prevalence results from socioeconomic
factors, including easy access of palatable food, consumption of processed
foods, and a shift towards a sedentary lifestyle and insufficient physical activity
[1].
Obesity itself is asymptomatic besides changes in an individual’s body weight
and stature. However, evidence suggests a positive correlation exists between
obesity and risk factors for several types of cardiovascular diseases. These risk
factors include elevated blood pressure (BP), fasting blood glucose, triglycerides
and reduced blood levels of high density lipoproteins (HDLs) [2]. Unfortunately,
despite increased awareness of the negative impacts obesity might have on an
individual’s overall health, the prevalence of obesity in the US has increased over
the past decades. Currently, over one third of the adult population in the US is
obese (BMI ≥ 30) and another third is classified as overweight (25 ≤ BMI ≤ 30)
1

(Table 1.3). The adult obesity rate increased from 32.2% (2003-2004) to 34.9%
(2011-2012), with 33.5% of men and 36.1% of women considered to be obese
[3]. While childhood obesity has also increased, childhood obesity rates have
remained stable in recent years [3]. This is important because childhood obesity
frequently persists into adulthood, with up to 80% of obese children reported to
become obese adults [4].
1.2 Obesity-induced hypertension
Like obesity, hypertension is one of the major risk factors for cardiovascular
diseases. Hypertension is a chronic medical condition in which the BP in the
arteries is persistently elevated (see Table 1.4 for detailed classification).
Numerous clinical and basic research studies indicate that this chronic condition
is multifactorial in nature. Although the etiology of hypertension is not fully
understood, a close link between obesity and hypertension has been recognized
both in children and adults [5] [6]. According to data from the Third National
Health and Nutrition Survey (NHANES III), the prevalence of hypertension has
increased significantly in both men and women and is much higher in overweight
and obese subjects [7]. It has been estimated that roughly 60-70% of
hypertension in adults may be attributed to adiposity [8]. Obese individuals
exhibit higher BP from childhood to old age and the difference in BP even exists
in the normotensive range. Moreover, obese individuals have a 3.5-fold
increased likelihood of having hypertension compared to lean subjects.
Epidemiology studies suggest a nearly linear relationship between BMI and
hypertension in different populations [9]. Interestingly, many studies suggest that
2

centrally located body fat is a more reliable determinant of elevated BP than
peripheral fat in both genders, and the relationship between central adiposity,
measured as waist-hip ratio, and BP appears to be independent of BMI [10].
Research

aimed

to

understand

the

underlying

pathophysiological

mechanisms of obesity-related hypertension reveal its complexity. Different
factors involving multiple systems are suggested to play a role in obesity-related
hypertension. Environmental, physiological and genetic factors come together to
influence the impact of obesity on BP. Although more studies are required to
explore further in this area, it is worthwhile to understand the mechanisms of
obesity-related

hypertension,

for

that

may

have

important

therapeutic

implications. Several key systems and factors have been implicated in the
pathogenesis of obesity-induced hypertension, including activated sympathetic
nervous system (SNS), stimulated renin angiotensin system (RAS), impaired
endothelial function, and insulin resistance [8](Table 1.5).
1.2.1 Sympathetic activation
Neural control mechanisms provide very precise, short-term cardiovascular
regulation. However, numerous studies have demonstrated that the nervous
system also contributes to long-term cardiovascular and BP control. The neural
control of chronic arterial pressure involves primarily the sympathetic division of
the autonomic nervous and the associated neurohormonal systems [11]. Much
experimental evidence exists to implicate the SNS in the etiology of obesityhypertension. For instance, in an early experimental model of obesity caused by
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ventromedial hypothalamic injury in rats without overfeeding, SNS was
suppressed [12], but the BP were elevated in the obese rats of both sex [13]. In
contrast to hypothalamic obesity, models of obesity caused by overfeeding,
which mimics the human condition, showed quite opposite observations. In one
study, high fat (HF) feeding (consisting of 2 pounds of cooked beef fat or lard in
addition to regular diet of one can of dog food) for 6 weeks in dogs resulted in
significantly increased body weight associated with an increase in mean arterial
pressure (MAP) [14]. In addition, dogs in the HF diet group retained significantly
more sodium than the control group and had significantly increased plasma
norepinephrine and aldosterone concentrations [14]. In support of the possibility
that activated SNS contributes to obesity-hypertension in dogs, Hall et al.
showed that administration of combined α- and β-adrenergic blockers for 7 days
lowered BP to a much greater extent in obese hypertensive dogs compared to
lean dogs [15]. Similarly, rats fed a HF diet exhibit rapid weight gain and
increased MAP, and the increased MAP can be blunted by ganglionic blockade
indicating a stimulated SNS in rodent model of obesity-hypertension [16].
Experimental animals of different species respond similarly to over-nutrition,
exhibiting common features such as rapid weight gain, activated SNS and
elevated BP. Researchers postulated that activated SNS is an adaptive
mechanism that initiates thermogenesis to protect against overfeeding and
maintain body weight [17]. However, this is achieved at the price of activated
SNS to the kidneys and vasculature, which contributes to obesity-hypertension.

4

In humans, SNS activity or peripheral catecholamine levels are not always
increased in obese subjects; however, changes in organ-specific SNS activity
were documented in both obese normotensive and hypertensive subjects. In
obese humans with normal BP, SNS activity is elevated in kidneys and skeletal
muscle vasculature but suppressed in heart, with no change in sympathetic
outflow to skin and hepato-mesenteric circulation [18, 19]. Similarly, sympathetic
outflow to kidneys and vasculature are also elevated in obese hypertensive
subjects. However, the suppression of cardiac SNS seen in normotensive obese
is absent in these populations [20].

Moreover, studies also failed to identify

further elevations in renal SNS in obese, hypertensive patients compared to
obese subjects with normal BP [21]. Thus, it is still unclear whether and to what
extent these changes in organ-specific SNS contribute to the etiology of obesityrelated hypertension in humans, but to date this is a possible link between
obesity and hypertension.
It has been proposed that activated SNS in obesity might be the consequence
of increased plasma leptin levels [22]. Leptin, an amino-acid hormone produced
almost exclusively by white adipose tissue, plays an important role in regulating
food intake and maintaining body weight homeostasis. However, it is believed
that leptin activity may also increase BP through the enhancement of SNS [23].
Plasma concentrations of leptin are closely associated with the adipose tissue
mass and are elevated in obese human subjects [24]. Moreover, studies showed
that significantly more leptin was needed to result in inhibition of food intake in
mice with diet-induced obesity than was required for comparable effects in lean
5

mice fed a standard murine diet [25]. Thus, it is very likely that resistance to
leptin develops with increased plasma concentrations of leptin in obese subjects.
However the resistance to leptin may be selective such that the effect of leptin on
appetite is lost, whereas that on stimulating SNS is preserved. In humans,
several studies have suggested plasma leptin levels to be positively correlated
with BP in both obese and non-obese individuals [26-28]. Taken together,
hyperleptinemia that occurs in obesity due to a selective leptin resistance may be
a major mechanism for elevated SNS activity and consequent obesityhypertension.
1.2.2 Insulin resistance
Early opinion with regard to the involvement of insulin response in the
pathology of obesity-hypertension was derived from the assumption that elevated
serum insulin concentrations as a consequence of overfeeding resulted in SNS
activation

and

subsequent

hypertension

[29].

Fasting

serum

insulin

concentrations are higher in obese individuals [30] and insulin infusion in humans
with clamping of blood glucose stimulates sympathetic outflow to skeletal muscle
vasculature

[31].

However,

obesity-accompanied

increases

in

renal

norepinephrine spillover were demonstrated not to be quantitatively related to
serum insulin concentrations [32]. Moreover, renal SNS was not stimulated in
humans with euglycemic insulin infusion [33], suggesting mechanisms for insulinmediated obesity-hypertension distinct from activated SNS.
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It is well known that central obesity is commonly associated with insulin
resistance and consequent hyperinsulinemia. Insulin action in vascular smooth
muscle cells (VSMC) results in the production of cyclic guanine nucleotide
monophosphate (cGMP), reduction of calcium, and consequent vasorelaxation
[34]. This insulin-mediated vasorelaxation in VSMCs may be impaired in obese
individuals who develop insulin resistance. In addition, hyperinsulinemia may
activate the mitogen-activated protein kinase (MAPK) pathway resulting in
enhanced vasoconstriction [34]. Moreover, hyperinsulinemia increases sodium
reabsorption and water retention in the kidney associated with increased BP [35].
1.2.3 Endothelial dysfunction
The vascular endothelium plays an important role in maintaining vascular
homeostasis. It is critical that the endothelium not only serves as a physical
barrier but also actively regulates the basal vascular tone and reactivity under
normal conditions. Impaired endothelial function has been suggested to
contribute to the development of obesity-hypertension [36]. Endothelial
dysfunction, featured by a functional alteration in the control of vascular tone as
well as structural changes in vascular biology, is present in obese humans and
the associated comorbidities [37]. The severity of endothelial dysfunction
correlates with the degree of visceral adiposity [38]. A human study showed that
endothelium-dependent vasodilation in resistance arteries is impaired in obese
hypertensive women administered acetylcholine via iontophoresis compared to
control lean subjects [39]. In addition, obese women also exhibited impaired skin
capillary recruitment after arterial occlusion.
7

Although the underlying

mechanisms for endothelial dysfunction in obesity haven’t been fully established,
results obtained from obese hypertensive animal models suggested the
involvement of vascular proinflammatory factors as well as enhanced oxidative
stress. HF-fed mice with obesity-hypertension exhibit impaired vascular
relaxation in response to acetylcholine which is associated with local activation of
the NF-kB pathway and reduced antioxidant defense [40]. In addition, activation
of the NF-kB pathway and increased superoxide (O2-) production were observed
in the vascular wall of angiotensin II-(AngII) induced hypertensive rats [41].
Studies in human as well as in animal models demonstrated a strong association
between RAS and obesity-hypertension, which will be discussed in Section 1.5.
1.3 Gender differences in obesity-hypertension
Men and women are physiologically different, and this is also true when it
comes to the risk for cardiovascular diseases (CVD). Gender differences have
been reported for traditional CVD risk factors such as obesity, diabetes, and
hypertension [42-44]. In fact, the prevalence, severity, and management of those
CVD risk factors may also differ between men and women. Several gender
differences exist in BP, a critical component in the regulation of the
cardiovascular system. Firstly, BP itself displays a sexually dimorphic pattern in
humans throughout life. The mean BP in men is generally higher than that in
women regardless of age [44]. Both men and women showed age-related
increases in systolic blood pressure (SBP) and SBP is slightly higher in men
during early adulthood. However, this situation is largely reversed with increasing
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age, where the age-related rate of rise in BP is higher for women, with SBP
levels becoming similar to that of men [44].
Secondly, the prevalence of hypertension also differs between genders.
According to the CDC, the prevalence of hypertension in adult men is much
higher in all age groups than women in the same age group before age 45 [45].
However, this situation is again being reversed in older age groups, where the
prevalence of hypertension in women catches up and exceeds that of men
(Table 1.6). One obvious common feature for women in this age group is the
natural physiological change called menopause, where female hormone
production by the ovaries decreases dramatically. Whether and to what extent
menopause or associated reduction in hormone levels contributes to the
increased hypertension prevalence in women in those older age groups has not
yet been fully defined. What complicates the issue further is that menopause is
also associated with changes in body fat distribution and increased obesity
prevalence in women. The question then becomes whether the dramatic
increase in hypertension prevalence is associated with or secondary to the
increased obesity prevalence in women after menopause. In studies examining
the prevalence of hypertension between NHANES III (1988-1994) and NHANES
1999-2004, a rise in BMI has been suggested to be the primary factor
contributing to the rising prevalence of hypertension in men but not as much in
women [7]. In contrast, a large historical cohort study performed in a Japanese
population examining sex and age differences in the effect of obesity on
hypertension incidence suggested that the effect of obesity (measured as BMI)
9

on hypertension incidence is stronger in women than in men [46]. However, one
thing to keep in mind when interpreting these data is that BMI alone as a marker
for obesity is not quite precise, because it doesn't directly reflect the quantity and
distribution of adiposity in an individual. In fact, results from human studies
suggest that conicity index (index of abdominal adiposity, a function of abdominal
girth, weight, and height) [47] and waist-to-hip ratio are better indices of obesity
in predicting cardiovascular risks in both men and women [48]. In addition,
conicity index is a better predictor of BP and insulin levels in healthy
premenopausal women [49], whereas waist-to-hip ratio correlates well with
estradiol concentrations in young women [50]. While there is still controversy
regarding the effect of sex on the association between obesity and hypertension,
the association between the two tend to become weaker with increasing age [51],
suggesting the possible role of sex hormones such as estrogen as mediators of
sex differences in the incidence of obesity-hypertension.
To better understand the effect of sex on obesity-hypertension, studies using
animal models have generated interesting results which may provide important
insight for such conditions in humans. Rats of both genders fed a cafeteria diet
(four palatable foods for human consumption in addition to chow) for 10 weeks
exhibit the same increase in fat pad weights and plasma leptin levels [52]. Obese
male rats had elevated BP (25 mmHg) associated with an increase in α2adrenergic receptor densities in kidneys. In contrast, obese female rats had
normal blood pressure with unaltered renal α2-adrenergic receptor subtype
expression [52]. Similarly, male mice fed a HF diet (60% kcal as fat) develop
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obesity-hypertension, whereas female mice don't despite robust obesity [53]. The
sex differences in the development of obesity-hypertension in this model are
associated with changes in tissue-specific renin angiotensin components and
circulating angiotensin peptides concentrations. Moreover, ovariectomy (OVX)
conferred obesity-hypertension in HF-fed female mice and blunted the gender
differences [53], suggesting the involvement of sex hormones in the development
of obesity-hypertension in mice.
1.4 Renin angiotensin system (RAS)
The RAS is known for its role in the maintenance of body fluid, electrolyte
homeostasis, and the regulation of BP. The RAS is an enzymatic network that
functions through the actions of angiotensin peptides at their receptors both
systemically and locally (Figure 1.1). The whole system relies on a common
precursor protein, angiotensinogen (Agt). Agt is a globulin secreted mainly by
liver hepatocytes in lean individuals and by adipose tissue to a certain extent,
especially in obese individuals [54]. Agt is cleaved by renin, an enzyme produced
by juxtaglomerular (JG) cells in the JG apparatus in the kidney, to form the ten
amino acid peptide, angiotensin I (AngI). AngI is biologically inactive until it is
subsequently cleaved by angiotensin converting enzyme (ACE), which is mainly
present in the vascular endothelium of the lungs, to form AngII. AngII is one of
the main bioactive angiotensin peptides of the RAS and it exerts its effects via
the angiotensin receptor type 1 (AT1R) or angiotensin receptor type 2 (AT2R).
AngII action via AT1R induces vasoconstriction and adrenal release of
aldosterone, resulting in renal sodium and water retention and increased BP [55,
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56]. Stimulation of AT2R, however, usually exerts BP lowering effects [57]. AngII
can be processed further by aminopeptidases to generate angiotensin 2-8
(AngIII) and angiotensin 3-8 (AngIV) and by decarboxylation of Asp to form
angiotensin A (Ang A) [58]. Both AngIII and Ang A are reported to exert pressor
effects via AT1R similar to that of AngII but with less potency in vivo [59]. AngIV
acts on angiotensin receptor type 4 (AT4R) and is capable of mediating memory
acquisition as well as regulation of blood flow [60]. In addition, enzymes such as
chymase, kallikrein and cathepsins are responsible for ACE-independent AngII
formation in human tissues [61]. For instance, chymase is thought to be an
important AngII-generating enzyme in the human heart [62]. Since AngII is the
main effector peptide of the RAS and increases blood pressure via AT1R, ACE
inhibitors (ACEI) and AT1R blockers (ARBs) are clinically used as antihypertensive drugs to lower BP.
1.4.1 Angiotensin converting enzyme 2 (ACE2)
ACE2 is a functional component of the RAS, first discovered by two separate
groups in 2000 [63] [64], as a human homologue of ACE (40% identity). ACE2 is
a metalloprotease that contains a single HEXXH zinc-binding motif with the
primary role of converting AngII to angiotensin-1-7 (Ang-(1-7)). ACE2 also
catalyzes the conversion of AngI to angiotensin-1-9 (Ang-(1-9)), but the efficacy
of this reaction is about 400-fold less than that of the hydrolytic action on AngII
[65]. The ACE2 gene maps to chromosomal location Xp22 and contains 18
exons with an open reading frame encoding 805 amino acids. The complete
ACE2 protein includes an N-terminal signal peptide, a catalytic site, a
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transmembrane domain, and a C-terminal anchor. As a metalloprotease, ACE2
activity can be inhibited by EDTA but not by classical ACEI such as captopril or
lisinopril despite the high structural similarity with ACE. Early studies reported a
fairly restricted expression of ACE2 in heart, kidney and testis [63]. However,
more recent studies suggest a widespread expression in the GI tract, lungs,
ventricles and interestingly, in adipose tissue [66-68]. Since its discovery 15
years ago, ACE2 has attracted substantial research interest and has emerged as
an important regulator of the cardiovascular system. Because of its ability to
hydrolyze AngII and synthesize Ang-(1-7), ACE2 is now being recognized as a
critical component of the RAS which acts as a brake to the classic Ang II/AT1R
pathway.
1.4.2 Mas receptor (Ang-(1-7) receptor)
The human Mas oncogene, first known for its tumorigenic properties, was
later revealed to encode a protein that shares structural similarity with groups of
transmitter and hormone receptors [69]. In 2003, Santos et al demonstrated that
the Mas oncogene encoded a G protein-coupled receptor that functions as a
distinct, endogenous receptor for Ang-(1-7) [70]. Genetic deletion of Mas
receptors (MasR) abolishes the binding of radiolabeled Ang-(1-7) to mouse
kidney [70]. In addition, aortas from MasR deficient mice exhibit an impaired Ang(1-7)-induced relaxation response [71].

Ang-(1-7)/MasR signaling results in

endothelial release of nitric oxide (NO) via the PI3K/Akt pathway, and can
counter-regulate the deleterious effects of AngII/AT1R signaling by inhibiting
AngII-mediated protein kinase C (PKC) and ERK1/2 activation [72, 73]. An
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interesting study looking at the effect of Ang-(1-7) on perfusion pressure in
isolated mouse hearts showed that Ang-(1-7) decreases perfusion pressure only
in the presence of losartan (an AT1R antagonist) which can be blocked by a
MasR antagonist with no such effects being observed in hearts from MasR
deficient mice [74]. In contrast, in the presence of an AT2R antagonist, Ang-(1-7)
perfusion results in a significant increase in perfusion pressure which was not
affected by adding a MasR antagonist [74]. Interestingly, in transfected
mammalian cells, Kostenis et al showed that AngII/AT1R-mediated signaling was
suppressed by 50% with co-expression of MasR. Further investigation revealed a
physical interaction of MasR and AT1R to form heterodimers resulting in reduced
functionality of AT1R [75]. All these findings suggest complex interactions of the
Ang-(1-7)/MasR axis with classic Ang II pathways involving AT1R and AT2R in
regulating vascular effects.
1.5 Role of RAS in obesity hypertension
An over-activated RAS is one of the key systems implicated in the etiology of
obesity-hypertension. In humans, obesity is associated with increases in plasma
concentrations of Agt, renin, ACE and AngII [76, 77]. An increase in plasma
renin activity is documented in most obese subjects despite marked sodium
retention and increased body fluid, which leads to further sodium reabsorption
and elevated BP [78]. This increase in plasma renin activity in obese subjects is
likely secondary to the increase in SNS activity [79]. In contrast, weight loss in
obese subjects was associated with a reduction in plasma renin activity and
reduced BP [80]. In a population survey, Cooper et al demonstrated a positive
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association between BMI and serum ACE concentrations. Obese individuals with
BMI over 31 had significantly higher serum ACE, which persisted in multivariate
analysis controlling for BP and hypertension status, suggesting a potential
pathway through which obesity leads to elevation of BP [81]. Obese adults
(average BMI 35.7) who underwent dietary weight loss with a mean decrease in
body weight of 6 ± 3%, exhibited significant reductions in both systolic and
diastolic BP paralleled with a decline in serum ACE activity [82].
As a common precursor of angiotensin peptides in the RAS, plasma Agt has
been reported to be positively related to BP. A study looking at the relationship
among plasma Agt concentrations, BMI, and BP in human subjects suggested
positive correlations between BMI and plasma Agt, mean BP and plasma Agt,
and BMI and mean BP [83]. Genetic variant analysis of the human Agt gene
indicated a strong association between waist-to-hip ratio and systolic BP and Agt
T174M polymorphism in male subjects [84]. Human subjects homozygous for TT
genotype of the Agt M235T polymorphism were noted to have a blunted renal
vascular response to exogenous AngII, which was even more pronounced in
obese subjects [85]. Moreover, the Agt M235T polymorphism was also
associated with increased diastolic BP in Canadian women with substantial fat
mass [86]. These results suggest that there might be a genetic component
associated with regulation of Agt contributing to obesity-hypertension.
Although the classic RAS is mainly systemic and functions in an endocrine
fashion, studies support the presence of a local RAS in various tissues and
organs, including adipose tissue. Cassis et al in 1988 demonstrated the presence
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of Agt mRNA and protein in both brown and white adipose tissue in rats [87].
Similarly, a study examining tissue expression of Agt in rats during development
demonstrated adipose tissue over liver as the primary source of Agt in rat fetuses
[88]. Interestingly, adipocytes and/or preadipocytes are demonstrated to be the
cell types responsible for Agt production in several other tissues besides white
and brown fat depots, including aorta, atria, mesentery, and lung [89, 90]. Agt
mRNA and Agt release from adipocytes isolated from epididymal fat in rats was
reduced upon fasting (3 days) and increased by refeeding (6 days), and the
changes were specific to adipocytes with no change in hepatic production of Agt
and plasma Agt levels [91]. Importantly, changes in SBP in those rats paralleled
changes in adipocyte production of Agt, indicating a role for adipose Agt in
regulating BP. In addition, adipocyte Agt exerts hormonal and nutritional
regulation by insulin, fatty acids, and androgen, molecules that closely associate
with obesity.
Adipose tissue may be a critical site for Agt production in obese subjects.
Numerous studies have reported elevation of adipose Agt in human and animal
models of obesity [91-93], whereas weight loss led to reductions in adipose and
plasma Agt levels [76]. Indeed, adipose tissue may contribute up to 30% of
plasma Agt levels in obesity [94]. A 20% increase in systemic Agt achieved by
overexpression of Agt in adipose tissue resulted in increased BP in mice [94].
Mice with adipocyte deficiency of Agt have comparable weight gain with control
mice when fed a HF diet. Adipocyte deficiency of Agt had no effect on obesityinduced increases in plasma Agt concentrations but prevented the obesity16

induced elevation in plasma AngII concentrations and obesity-hypertension [95].
Together, these data suggest an adipose Agt-dependent activation of the
systemic RAS.
Interestingly, recent studies using a hepatocyte-specific Agt deficient mouse
model demonstrated possible crosstalk between systemic and adipose RAS.
Mice with hepatocyte-specific Agt deficiency on a low-density lipoprotein receptor
deficiency (LDLr-/-) background exhibited reduced body weight gain compared
with wild type littermates when challenged with a western diet, which was mostly
attributed to reduced fat mass [96]. However, hepatocyte-specific Agt deficiency
in mice on a C57BL/6 background had no effect on the development of HF dietinduced obesity, but markedly reduced the content and release of Agt from
adipose explants, and resulted in markedly decreased BP associated with
reduced plasma AngII concentration [97]. Results from this study suggest that
Agt deficiency may resulted in limited megalin-dependent uptake of Agt into
adipocytes for local production of AngII, since adipose derived AngII can be the
major source of circulating AngII and contribute to hypertension in obese
mice[95]. It is not very clear however, whether adipose tissue is another source
for renin. Early studies by Shenoy et al reported undetectable renin mRNA by
PCR in rat brown adipose tissue, but the presence of renin activity in isolated
brown adipocytes [98]. Similarly, renin activity was found in the adipocyte fraction
isolated from rat epididymal fat pads whereas renin mRNA was detected in the
stromal-vascular fraction [99].

Additionally, renin mRNA and activity were
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detected in human adipose tissue as well as in primary cultured human
preadipocytes [100].
1.6 Role of ACE2/Ang-(1-7)/MasR axis in obesity-hypertension
1.6.1 Ang-(1-7) and BP regulation
Ang-(1-7) was first identified as a heptapeptide that accumulates in canine
brainstem homogenate when hydrolysing labeled Ang I [101]. Ang-(1-7) was
initially thought to be an inactive metabolite of AngII, since the C-terminal residue
of AngII is critical for its biological function. However, studies by the Ferrario
group demonstrated an equipotence of Ang-(1-7) and AngII to stimulate
vasopressin release from rat hypothalamo-neurohypophysial systems [101],
suggesting Ang-(1-7) may function as a neuromodulator [102]. This was the first
evidence showing functional cardiovascular effects of Ang-(1-7).
Determination of the overall effects of Ang-(1-7) is complicated by the fact
that Ang-(1-7) actions in the central nervous system are likely different from
region to region [103] and are dose dependent [104]. Unilateral injection of a low
dose (0.1 to 12.5 ng) of Ang-(1-7) into the rat dorsal medulla triggers monophasic
depressor effects, whereas a high dose leads to biphasic depressor-pressor
responses [104]. Administration of Ang-(1-7) to Sprague-Dawley rats via femoral
vein triggers cardiovascular actions consisting of a short pressor phase followed
by a long depressor phase which were not completely inhibited by AT1R or AT2R
antagonists [105] suggesting the involvement of a distinct angiotensin receptor.
Interestingly, intravenous infusion of Ang-(1-7) at the dose of 10 or 100 µg/kg/min

18

showed no effect on resting BP in anesthetized rats, but inhibited AngII induced
pressor responses [106]. Similarly, central administration of affinity-purified Ang(1-7) antibody resulted in significant elevations in BP in transgenic hypertensive
rats but had no effect in normotensive rats [107]. These studies suggest
opposing actions of Ang-(1-7) and AngII in mediating BP responses in rodent
models and also suggest that effectiveness of Ang-(1-7) relies on an activated
AngII pathway.
1.6.2 ACE2 and BP regulation
The discovery of ACE2 and the MasR brings new interest into further
investigation of the potential role of this non-classic arm of the RAS in BP
regulation and as a new target for treating hypertension. The ACE2 gene maps
to a defined quantitative trait locus (QTL) originally identified as a QTL for BP
[108], suggesting a potential role of ACE2 in BP homeostasis. Studies that aimed
to determine associations between ACE2 genetic variants and hypertension
showed mixed results. The first study, in 2004, investigated 4 different SNP in
introns of the ACE2 gene and their frequencies in male and female Australian
individuals (white Anglo-Celtic origin) with or without essential hypertension (EH)
and showed no association of ACE2 polymorphisms with EH. In contrast,
association of ACE2 SNP G8790A with EH was suggested in a Chinese
population. The A allele frequencies were significantly higher in patients with EH
than those with normal BP in both genders [109]. Additionally, a GG genotype of
ACE2 polymorphism in female patients with metabolic syndrome was associated
with higher diastolic BP [110]. Moreover, studies in patients in India as well as in
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populations of European descent also showed associations between ACE2 gene
polymorphisms and hypertension which varies among ethnicity and genders
[111, 112].
However, it is not clear whether these SNPs in the ACE2 gene result in
changes in gene expression, protein function of ACE2, or even changes in
systemic RAS. The Penninger group in 2002 examined ACE2 expression in rat
models of hypertension and revealed that ACE2 mRNA and protein expression
were markedly reduced in kidneys of all three hypertensive rat strains. Moreover,
targeted disruption of the ACE2 gene in mice resulted in significant elevations in
AngII levels in kidney, heart and plasma, although there is no apparent change in
BP in this particular study [108]. Other groups reported either increased or
unchanged BP in ACE2 null mice compared to wild type control mice with
different backgrounds [113, 114]. Nevertheless, region-specific overexpression of
ACE2 showed promising effects on reducing blood pressure in rodent models of
hypertension. Long-term overexpression of transgenic ACE2 in the rostral
ventrolateral medulla (RVLM) decreased BP (15 mmHg) in spontaneously
hypertensive rats but not control Wistar-Kyoto rats [115]. In an AngII-induced
hypertensive model, overexpression of ACE2 in paraventricular nucleus (PVN) of
male Sprague-Dawley rats significantly attenuated AngII-induced increase in BP
(about 30 mmHg reduction) but had no effect on resting BP in control rats without
AngII infusion. Interestingly, ACE2 overexpression in male rats also led to
decreased ACE and AT1R but increased MasR and AT2R expression in PVN
[116]. Similarly, neuronal overexpression of ACE2 in the brain reduces BP in
20

DOCA-salt treated mice associated with reductions in hypothalamic Ang II levels
[117]. Besides the central effects of ACE2 in BP regulation, spontaneously
hypertensive stroke-prone rats (SHRSP) with transgenic expression of human
ACE2 in VSMCs exhibit reduced MAP compared to control rats and this was
associated with an improvement in vascular endothelial function [118]. In
addition, intra-cardiac expression of ACE2 significantly attenuated high BP and
cardiac fibrosis in SHR but not in WKY control rats [119]. These data suggest a
role of tissue-specific ACE2 in BP regulation.
1.6.3 Factors regulating ACE2
1.6.3.1

Diet

A large spectrum of molecules and factors exert regulation over ACE2 in vitro
and in vivo, including diet, physical activity, and drugs that modulate the RAS. In
rats, adult offspring from food-restricted (70%) dams throughout gestation exhibit
mild elevations in BP, and a two-fold increase in ACE2 activity with no difference
in mRNA expression in lung compared to control rats [120]. In SHR that received
daily injections (IP) of all-trans retinoic acid for 1 month showed a significant
increase in ACE2 gene and protein expression in heart and kidney associated
with a reduction in BP compared to placebo-treated SHR. However these effects
were not observed in WKY controls rats that received similar treatments [121].
The Cassis group in 2008 reported expression of ACE2 in 3T3-L1 adipocytes
and adipose tissue of obese male mice. Interestingly, short term HF-feeding (one
week) in male mice resulted in a threefold increase in ACE2 gene expression
paralleled with increased ACE2 activity in adipose tissue and no change in BP. In
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contrast, mice with chronic HF-feeding for 4 months exhibited elevated adipose
ACE2 mRNA but unaltered ACE2 activity and hypertension compared to LF-fed
animals [122]. This inconsistency between ACE2 mRNA and ACE2 activity
suggested a possible post-translational regulation mechanism of ACE2, which
might be activated by chronic HF feeding contributing to ACE2 dysregulation and
hypertension. In another study, rats with high sucrose intake exhibited high BP
and increased ACE2 gene and protein expression in epididymal adipose tissue,
but not in kidney [123]. Porcine adipocytes treated with polyunsaturated fatty
acids (PUFAs) (arachidonic acid, conjugated linoleic acid and docosahexaenoic
acid) exhibited decreased ACE2 mRNA abundance after 48 hour incubation and
the effects of these PUFAs on ACE2 expression were associated with the
production of eicosanoid, the common metabolites of three PUFAs [124]. These
findings suggest nutritional regulation of ACE2 by diet and dietary components
that could be tissue-specific, and moreover, that adipose can be a critical site for
ACE2 regulation contributing to BP homeostasis.
1.6.3.2

Exercise

A recent study in SHR demonstrated that chronic aerobic exercise training
increased mRNA and protein expression of ACE2 and MasR as well as Ang-(1-7)
levels in aorta which may contribute to reduced BP and aortic remodeling. In
addition, exercise training in SHR resulted in changes in microRNA
concentrations targeting RAS components, including ACE2 [125]. Similar effects
of exercise training on ACE2 expression were evident in the brain [126] and heart
[127] of trained animals in separate studies. Another mechanism contributing to
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the protective effect of exercise training via ACE2 may be related to a shedding
process mediated by the enzyme ADAM-17. As a member of a disintegrin and
metalloproteinase family, ADAM-17 has been implicated in the shedding of ACE2
ectodomain resulting in a soluble form with reserved enzymatic activity but
subject to urinary excretion [128, 129]. ADAM-17 can be stimulated by HF diet,
high glucose and insulin in vivo, but repressed by chronic exercise training. Daily
exercise training in db/db mice for 10 weeks reduced renal expression of
ADAM17, ACE2 shedding and urinary ACE2 excretion compared to sedentary
mice [130]. Studies in DOCA-salt hypertensive mice demonstrated increased
ACE2 activity in the cerebrospinal fluid as a result of increased shedding of
ACE2 from tissue membrane by ADAM-17, and a parallel reduction of ACE2
expression and activity in the hypothalamus. Moreover, knockdown of ADAM-17
prevented both the reduction of ACE2 in the brain and the associated DOCA-salt
induced hypertension in those mice [131].
1.6.3.3

Pharmaceuticals

ACE2 can also be regulated by drugs that target the classic RAS. When SHR
were administered the ARB telmisartan, rats exhibited reduced BP associated
with increased ACE2 expression in aorta compared to saline treated rats [132]. In
cultured human umbilical artery smooth muscle cells, treatment with telmisartan
ameliorated AngII-induced ERK1/2 and JNK phosphorylation and augmented
ACE2 protein expression [132]. Similarly, continuous administration of the ARB,
losartan, in SHR resulted in significant increases in renal ACE2 gene expression
[133]. ACEI therapy with lisinopril in rodent models was also associated with
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either increased ACE2 mRNA in heart or activity in the renal cortex paralleled
with elevated Ang-(1-7) concentrations in plasma or urine, respectively [134,
135]. In humans, diabetic hypertensive patients treated with telmisartan for 12
weeks were reported to have increased serum ACE2 content as well as ACE2
mRNA in monocyte-derived macrophages, partly contributing to the more
obvious therapeutic effect on lowering BP compared to patients receiving regular
treatments [136]. Hypertensive patients treated with olmesartan (an ARB), rather
than other antihypertensive agents (including calcium channel blockers, ACEI
and other ARBs) exhibited higher urinary ACE2 levels compared to control
patients taking no anti-hypertensive medications [137]. Interestingly, in two
controlled studies and a clinical trial of over 3000 untreated hypertensive
patients, an ACE2 polymorphism of rs2106809 T allele was associated with a
1.6-fold increased risk for hypertension and moreover, poor BP lowering in
response to captopril in women [138]. These data suggest that the
antihypertensive actions of ACE inhibitors and ARBs may in part be due to
increased activation of ACE2 to promote both AngII metabolism as well as Ang(1-7) formation.
Although the underlining mechanisms for pharmaceutical regulation of ACE2
by ACEI and ARBs have not been fully elucidated, one speculation would be the
ability of those antihypertensive agents to prevent ACE2 degradation by blocking
AngII-AT1R signaling. In ACE2-transfected Neuro-2A cells, AngII treatment led to
ACE2 internalization and degradation in lysosomes which could be prevented by
losartan or a lysosomal inhibitor [139]. In cells lacking endogenous AT1R, AngII
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failed to promote ACE2 internalization and degradation, which was rescued by
AT1R transfection. In addition, this group also demonstrated a physical
interaction of ACE2 with AT1R to form complexes by immunoprecipitation, and
AngII treatment reduced such interactions and promoted ACE2 ubiquitination
[139].
1.6.3.4

Sex steroids

The impact of sex steroids on the regulation of BP has always been of great
interest. The major female sex hormone, estrogen, is generally considered to be
cardiovascular protective and loss of estrogen may account for the higher BP
and hypertension prevalence in postmenopausal women [140]. Lots of studies
have demonstrated the ability of estrogen to regulate the RAS including
downregulation of ACE [141] and AT1R [142, 143], supporting the putative antihypertensive effects of estrogen (Table 1.7).
Interestingly, recent studies also demonstrated that estrogen positively
regulates ACE2 expression in a tissue-specific manner. Female rat offspring from
intrauterine growth restricted (IUGR) mothers exhibited significant increases in
renal ACE2 mRNA expression compared to control females. However, the
difference in renal ACE2 expression was blunted by OVX in female offspring of
IUGR but not control rats [144]. In the renal wrap model of hypertension, OVX
reduces ACE2 activity by 31% in the rat renal cortex compared to intact animals,
which was accompanied by reductions in ACE2 protein and mRNA expression.
However, the changes in ACE2 protein and activity were not observed in the
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heart of OVX animals. Moreover, E2 administration in OVX rats prevented the
renal loss of ACE2 [145].
Studies investigating the effects of ACE2 during pregnancy reported
increased ACE2 expression in kidney and reproductive organs associated with a
reduction in BP during the third trimester of pregnancy in both normotensive and
hypertensive rats [146]. Similarly, the increase of ACE2 protein and activity in the
renal cortex and medulla of pregnant animals in late gestation were consistent
with the high levels of estrogen found in those pregnant animals [147]. However,
it is not clear whether and to what extent positive regulation of ACE2 by
endogenous estrogen contributes to the relatively lower hypertension rate in
women compared to age-matched men prior to menopause. Moreover, it is
unclear whether the increase in hypertension prevalence in postmenopausal
women is due to loss of estrogen regulation of RAS components, including
ACE2.
Studies by the Cassis group demonstrated that ACE2 mRNA abundance in
3T3-L1 adipocytes can be increased by treatment with estrogen but not
progesterone or testosterone [53]. Moreover, HF-fed obese male mice exhibiting
significant reductions in renal ACE2 activity (with no change in adipose ACE2),
associated with increased AngII and decreased Ang-(1-7) in plasma contributed
to elevated BP compared to LF controls. In contrast, HF fed obese female mice
displayed marked increases in adipose ACE2 activity associated with increased
Ang-(1-7) in plasma, and were resistant to obesity-hypertension [53]. More
importantly, OVX resulted in a significant reduction in adipose but not renal ACE2
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activity as well as plasma Ang-(1-7) concentrations, and conferred obesityinduced hypertension in HF-fed females. In addition, deficiency of ACE2 or
administration of D-Ala-Ang-(1-7), a MasR antagonist, significantly increased BP
in HF-fed female mice [53]. These data suggest that the tissue-specific regulation
of ACE2 by diet-induced obesity and female sex hormones leads to changes in
the AngII/Ang-(1-7) peptide balance, contributing to the diverging susceptibilities
of males versus females to obesity-hypertension.
1.7 Role of RAS in CVDs
It has been recognized for decades that the classic RAS is implicated in the
pathogenesis of cardiovascular diseases other than hypertension. Large
observational as well as clinical trials using ACEI or ARBs in patients with heart
failure showed promising beneficial effects on improving survival and attenuating
cardiac remodeling [148, 149], suggesting the important role of AngII in cardiac
pathology. Indeed, ACEI and ARBs are first line medications in the treatment of
heart failure.
AngII, the primary effector peptide of the RAS, functioning through the AT1R,
contributes to cardiac and vascular growth and remodeling. AT1R, via G protein
activation, stimulates phospholipases C, D, and A2 resulting in the generation of
IP3/Ca2+, diacylglycerol/protein kinase C (DAG/PKC) and arachidonic acid [150].
In turn, multiple downstream signaling cascades can be activated resulting in
vascular and cardiac contraction, endothelial dysfunction, hypertrophy, fibrosis,
and remodeling. Both systemic and locally generated AngII are thought to be
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implicated in these processes. A large body of evidence suggests that AngII
acting through the AT1R activates cardiac fibroblasts resulting in increased extracellular matrix (ECM) deposition in the heart [151, 152]. Moreover, growth factors
released from cardiac fibroblasts act in a paracrine fashion to stimulate
cardiomyocyte hypertrophy [153, 154]. In addition, it is suggested that AngII may
directly contribute to cardiomyocyte hypertrophy via upregulation and activation
of Nox2 (NADPH oxidase 2), leading to excessive production of reactive oxygen
species (ROS) and activation of SERCA2 (sarcoplasmic reticulum Ca2+ATPase2) [155]. Studies investigating the cardiac RAS under pathological
conditions suggest that elevated AngII concentrations in the diseased heart may
be attributed to the increased availability of renin in the systemic circulation or
due to increased cardiac ACE expression [156].
In the vasculature, activation and/or upregulation of the Nox families including
Nox1, 2 and 4 [157] by AngII via AT1R result in excess ROS production in
vascular endothelium, triggering diverse downstream redox signaling pathways
which ultimately lead to endothelial dysfunction and inflammation [158]. In
addition, AngII also contributes to VSMC hypertrophy [157] and induces
mitochondrial dysfunction [159]. Drugs targeting the RAS, such as ACEI and
ARBs, as well as antioxidants and anti-inflammatory reagents were used to
reduce inflammation, slow remodeling and disease progression. Thus, it is clear
that the classical RAS plays an important role in the initiation and progression of
various vascular diseases.
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1.7.1 Role of ACE2/Ang-(1-7)/MasR axis in cardiac function
Despite therapeutic advances in treating cardiovascular diseases, the
morbidity and mortality of CVDs are still unacceptably high. Thus, great efforts
are continuously being made to explore potential new drug-able targets for
different aspects of CVDs. The ACE2/Ang-(1-7)/MasR axis, with its vasodilative
and growth inhibition nature, has been shown to exhibit protective cardiovascular
effects in a variety of ways, and thus could be a good candidate for therapeutic
development.
1.7.1.1

Ang-(1-7) and cardiac function

As the effector peptide of this counter-regulatory axis, the effects of Ang-(1-7)
on the heart have been extensively studied. In a rat model of ischemic
cardiomyopathy induced by ligation of the left coronary artery, Ang-(1-7)
immunoreactivity was significantly augmented in cardiomyocytes in the infarct
area and was associated with changes in cardiac contractility [160]. Likewise, in
human failing hearts of either idiopathic cardiomyopathy or in patients with
primary pulmonary hypertension, formation of Ang-(1-7) from
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I-AngII or
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I-

AngI as substrates was significantly increased compared to non-failing hearts
[161]. These data suggest that the increased presence of Ang-(1-7) in the failing
hearts of both human and experimental rat models may function as a
compensatory mechanism in response to the hemodynamic and structural
changes of the injured heart.
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In contrast, in SHR with salt-induced cardiac remodeling, excessive collagen
deposition was associated with diminished cardiac Ang-(1-7) independent of
changes in cardiac AngII levels, indicating that the loss of the effects of Ang-(1-7)
contributes to the cardiac dysfunction in this model [162]. In cultured rat cardiac
fibroblasts, Ang-(1-7) incubation inhibited collagen synthesis as assessed by a
collagenase-sensitive [3H]proline incorporation assay, and the effect was not
affected by valsartan. Moreover, pretreatment with Ang-(1-7) completely
prevented AngII-induced increases in collagen synthesis [163]. Transgenic rats
with overexpression of an Ang-(1-7)-producing fusion protein were demonstrated
to be more resistant to isoproterenol-induced cardiac stress [164]. Heart-specific
expression of the Ang-(1-7)-producing fusion protein, resulting in a significant
increase in cardiac Ang-(1-7) concentrations in heterozygous transgenic rats
compared with controls, led to a slight improvement in resting cardiac function.
When challenged with high dose of isoproterenol, Ang-(1-7) transgenic mice
showed a greater capacity to withstand stress and significantly less collagen I
and III deposition in the heart compared to controls [165].
Besides its anti-fibrotic effects on cardio fibroblasts, Ang-(1-7) has also been
shown to have antigrowth and anti-trophic effects on cardiomyocytes (Figure
1.2). In cultured neonatal rat myocytes, Ang-(1-7) significantly attenuated protein
synthesis indicated by less [3H]leucine incorporation into myocytes. In addition,
Ang-(1-7) reduced serum-stimulated ERK1/ERK2 MAPK activity, which was
blocked by either a selective Ang-(1-7) receptor antagonist or genetic silencing of
MasR via an antisense oligonucleotide [166].
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This suggests that Ang-(1-7)

inhibits cardiomyocyte growth through MasR-mediated inhibition of the MAPK
signaling pathway. Ang-(1-7) infusion via osmotic minipumps in Wistar rats
resulted in significantly increased plasma Ang-(1-7) and AngII concentrations, but
marked decrease of AngII levels in the heart with no change in renal AngII,
suggesting that the site-specific changes in cardiac AngII concentrations might
contribute to the beneficial effects of Ang-(1-7) in the heart [167]. Suprarenal
abdominal aortic coarctation resulting in pressure-overload induced left
ventricular hypertrophy and fibrosis, which were attenuated by chronic Ang-(1-7)
infusion. However, no change in cardiac AngII concentration was observed with
Ang-(1-7) administration in this study [168]. Mechanistically, Ang-(1-7) counterregulates AngII-induced cardiac injury through various signaling pathways,
including MAPK inhibition through activation of dual-specificity phosphatase 1
(DUSSP1)

[169],

oxidative

stress

elimination

through

upregulation

of

malondialdehyde (MDA) and superoxide dismutase (SOD) [170], as well as by
suppression of growth and inflammation via the nitric oxide (NO)/guanosine 3’,5’cyclic monophosphate (cGMP) pathway [171].
1.7.1.2

ACE2 and cardiac function

As one of the major enzymes responsible for formation of circulating Ang-(17) and the enzyme responsible for most of the Ang-(1-7) production from
exogenous AngII in isolated hearts from hypertensive rats [172], ACE2 has been
suggested to play a critical role in cardiac physiology and specifically may serve
as a compensatory mechanism in the pathology of cardiac remodeling. The
Penninger group in 2002 first demonstrated that mice with ACE2 deficiency
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exhibit significant reductions in cardiac contractility, as indicated by decreased
left ventricular fractional shortening, despite normal BP compared to control
mice. However the study failed to observe structural and biochemical changes
associated with cardiac hypertrophy or dilated cardiomyopathy besides slight
thinning of left ventricular wall and increased chamber dimensions. Interestingly,
reported changes in cardiac function in ACE2 null mice were found to be more
severe in male than in female mice and progressed with aging [108].
In contract, the Coffman group in 2006 reported a normal cardiac phenotype
in their genetic constructed ACE2-deficient mice [113]. Moreover, studies by a
Japanese group reported normal cardiac function and morphology in ACE2
deficient mice but increased susceptibility to pressure overload-induced cardiac
dysfunction. Those ACE2 null mice, in response to transverse aortic constriction
(TAC), exhibit marked increases in cardiac AngII and MAPK activity, developed
cardiac hypertrophy and dilation, and had increased cardiac death compared
with wild-type mice [114]. A recent study suggested that even heterozygote loss
of ACE2 is sufficient to increase susceptibility to heart disease. Heterozygote
female ACE2 mutant mice (Ace+/-), in response to AngII-induced pressure
overload, exhibit greater LV dilation and worsening systolic and diastolic
dysfunction associated with increased myocardial fibrosis and hypertrophy [173].
Pharmacological inhibition of ACE2 in hypertensive rats resulted in significant
increases in cardiac but not plasma AngII concentrations associated with
augmented LV interstitial collagen deposition and cardiomyocyte hypertrophy
[174].
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Interestingly enough, ACE2 has also been suggested to play an important
role in heart disease associated with obesity. Obese ACE2 null mice exhibit
increased epicardial adipose tissue (EAT) inflammation and pro-inflammatory
macrophage polarization associated with decreased myocardial adiponectin,
increased cardiac steatosis, and myocardial insulin resistance resulting in a
worsened heart function compare to wild type mice. Moreover, Ang-(1-7)
administration to HF-fed ACE2 null mice ameliorated EAT inflammation, cardiac
steatosis and normalized heart function [175]. Taken together, these results
suggest that the protective cardiac effect of ACE2 lies in its ability to suppress
the deleterious effects of Ang II either through direct catabolism of Ang II,
activation of Ang-(1-7)/MasR signaling pathway, or in some cases, both.
1.7.1.3

MasR and cardiac function

As the receptor for endogenous Ang-(1-7), MasR is highly expressed in
cardiomyocytes [176] and thus is responsible for the cardio-protective effects of
Ang-(1-7) signaling. Even prior to discovery as the receptor for endogenous Ang(1-7), the Mas receptor was reported to be an important determinant of heart
function in experimental animals. In particular, MasR deficient mice of both sexes
exhibit increased sympathetic tone and reduced heart rate variability (HRV). The
reduction in HRV is more pronounced in female MasR deficient mice and could
be a relevant predictor of cardiovascular risk in humans [176]. Further
investigation of heart function by echocardiography in MasR null mice showed
significant reductions in fractional shortening and posterior wall thickness in
systole [177] suggesting those mice have impaired cardiac contractile properties.
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Additionally, in isolated heart preps, MasR deficiency was associated with lower
systolic tension, reduced heart rate, and higher coronary vessel resistance [177].
In a mouse model of ischemia/reperfusion, isolated perfused hearts from MasR
null mice or wild type mice treated with A-799 (a MasR-specific antagonist)
exhibited increased perfusion pressure at baseline, decreased systolic tension,
and increased diastolic tension during reperfusion compared to wild type controls
[178]. Acute Ang-(1-7) treatment resulted in activation of endothelial NO
synthase and Akt and NO production in cardiomyocytes, however the Ang-(1-7)
dependent NO production was abolished in cardiomyocytes isolated from Mas
receptor-deficient

mice

or

cells

pretreated

with

A-779.

In

addition,

cardiomyocytes from MasR deficient mice exhibited impaired Ca2+ handling
compared to wild-type cardiomyocytes [179]. Taken together, these observations
reveal a key role of ACE2/Ang-(1-7)/Mas axis as a modulator of heart function
both in humans and experimental animals.
1.7.2 Role of ACE2/Ang-(1-7)/MasR axis in vascular function
There is a large body of evidence suggesting that the counter-regulatory arm
of the RAS also exhibits protective effects on the vasculature. Although effects
of ACE2 in vasculature could come from either reduced AngII or increased Ang(1-7), data from many in vitro and in vivo studies suggest that the beneficial
effects of ACE2 to maintain vascular homeostasis is largely Ang-(1-7)/MasR
dependent. The major signaling pathway associated with ACE2/Ang-(1-7)/MasR
regulation of vascular function is illustrated in Figure 1.3.
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Overexpression of ACE2 in human endothelial cells stimulated cell migration
and suppressed expression of monocytes and cellular adhesion molecules. In
this study, overexpression of ACE2 also attenuated AngII-induced production of
ROS. Interestingly, the effects of ACE2 to improve endothelial function were
attenuated by pharmacological inhibition of Ang-(1-7) with A779 [180].
Endothelial cells isolated from ACE2 null mice exhibited increased gene
expression of vascular adhesion molecule (VCAM), monocoyte chemoattractant
protein 1(MCP-1) and interleukin (IL)-6, as well as elevated inflammatory
responses to TNF-α stimulation [181]. In a mouse model of AngII-induced
abdominal aortic aneurysms (AAA), deficiency of ACE2 promoted AAA formation
[182]. In contrast, activation of ACE2 in wild type (LDLR-/-) mice by diminazene
aceturate (DIZE), an ACE2 activator, lead to a marked reduction in AAA
incidence (from 73% to 29%), which was associated with elevated plasma Ang(1-7) concentrations [182]. These results suggest that the protective effects of
ACE2 activation on AAA formation are attributed to increased Ang-(1-7)
production.
Numerous studies have demonstrated that Ang-(1-7) via MasR is able to
suppress VSMC proliferation and migration, mainly through inhibition of MAPK
and ERK1/2 activity. Interestingly, Ang-(1-7) treatment alone in SMC had no
effects on proliferation and migration. However, pre-incubation with Ang-(1-7)
abolished AngII – induced ERK1/2 activation and consequent SMC proliferation,
suggesting the ability of Ang-(1-7) to counter-balance AngII-mediated signaling in
VSMC. Moreover, the inhibitory effects of Ang-(1-7) in AngII-treated SMC were
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totally abolished by the MasR antagonist A-799 [183]. Additionally, Ang-(1-7)
acting via the MasR has also been shown to stimulate the release of
prostaglandins (PGI2 and PGE2), which in turn increase cAMP concentrations
resulting in inhibition of VSMC proliferation and migration [184].
Besides affecting VSMC function, Ang-(1-7) has been shown to improve
endothelial function through vasodilation. Ang-(1-7) via MasR has been shown to
increase PI3 kinase activity, leading to sustained phosphorylation of Akt and
subsequent activation of eNOS to increase NO bioavailability [73]. In addition,
increased NO bioavailability is associated with reduced ROS production, which
further contributes to the beneficial effects of Ang-(1-7). In a study looking at the
effect of Ang-(1-7) on salt-induced suppression of endothelium-dependent
vasodilation, chronic Ang-(1-7) infusion restored vascular relaxation in the
mesenteric arteries of high salt-fed rats [185]. Interestingly, the same effects
were observed in rats administered with the nonpeptide MasR agonist AVE0991, and were absent when treated with the MasR antagonist A-799 both
acutely or chronically, suggesting a MasR-dependent Ang-(1-7) pathway on
endothelial function. Moreover, pre-incubation with antioxidant or a NO donor
exerted protective effects to that of Ang-(1-7) to restore vascular relaxation. In
addition, superoxide levels were significantly ameliorated in rats with Ang-(1-7)
infusion or in arteries with Ang-(1-7) preincubation, indicating that Ang-(1-7)mediated reduction in ROS also contributes to the vasodilative effects of this
peptide [185]. There is also evidence to support the interaction of Ang-(1-7) with
AT2R and bradykinin receptors (BK2R) [186] to promote vasodilation, since in
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some cases the vasodilative response to Ang-(1-7) can be blocked by AT2R and
BK2R antagonists [187]. But these effects need to be clarified with further
studies. Nevertheless, MasR deficiency in mice on different backgrounds results
in reduced NO bioavailability, elevated ROS production and endothelial
dysfunction [188, 189]. This impaired endothelial function translated to increased
BP in MasR deficient mice on the FVB/N background which was corrected by an
antioxidant Tempol [188]. Taken together, these data support a protective role
for Ang-(1-7) acting through the MasR to regulate vascular function.
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Table 1.1 Classification of Overweight and Obesity in Adults According to
BMI

•

Classification

BMI, Kg / m2

Underweight

< 18.5

Normal range

18.5 – 24.9

Overweight

≥ 25.0 – 29.9

Class I obesity

30.0 – 34.9

High

Class II obesity

35.0 – 39.9

Very high

Class III obesity

≥ 40.0

Risk of Comorbidities

Increased

Extremely high

BMI indicates body mass index. Adapted from National Institutes of Health
and North American Association for the Study of Obesity. © 2000 National
Institutes of Health.
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Table 1.2 Ethnic Specific Values for Waist Circumference
Waist Circumference, cm
Country/Ethnic Group
Male

Female

North American

≥ 102

≥ 88

European

≥ 94

≥ 80

South Asian/Chinese

≥ 90

≥ 80

Japanese

≥ 85

≥ 90

Ethnic South and Central

Use South Asian

Use South Asian

Americans

recommendations

recommendations

Sub-Saharan Africans

Use European data

Use European data

Use European data

Use European data

Eastern Mediterranean and
Middle East (Arab)
populations
•

Adapted from Alberti et al. © 2006 John Wiley and Sons Inc.
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Table 1.3 Prevalence of High Body Mass Index (Overweight and O besity)
for Adults Aged 20 Years Older by Sex and Age, United States, 2011-2012
%(95% CI)
≥ 20 y

Classification
Crude

Age
Adjusted

20-39 y

40-59 y

≥ 60 y

60.3

75.3

71.6

BMI ≥ 25
All

Men

Women

69.0

68.5

(65.4-72.3) (65.2-71.6) (54.2-66.0) (72.1-78.2)
71.6

71.3

62.0

(68.0-75.0) (68.2-74.2) (56.2-67.5)
66.5

65.8

58.5

79.1

(67.0-75.8)
74.7

(74.8-82.8) (70.0-78.9)
71.7

(62.5-70.2) (62.0-69.5) (51.4-65.2) (66.2-76.6)

69.1
(63.2-74.5)

BMI ≥ 30
All

Men

Women
•

35.1

34.9

30.3

39.5

(32.3-38.1) (32.0-37.9) (26.6-34.4) (36.1-43.0)
33.7

33.5

29.0

39.4

(30.9-36.6) (30.7-36.5) (23.9-34.6) (36.0-42.9)
36.5

36.1

31.8

39.5

(32.9-40.3) (32.6-39.8) (28.3-35.5) (35.1-44.2)

35.4
(31.3-39.6)
32.0
(27.5-36.9)
38.1
(32.2-44.5)

Adapted from Cynthial L. et al. with modification. © 2014 American Medical
Association.

40

Table 1.4 Classification of Blood Pressure
Blood Pressure Level (mm Hg)
Classification
Systolic BP

•

Diastolic BP

Normal

< 120

AND

< 80

Pre-Hypertension

120 - 139

OR

80 – 89

Stage1 Hypertension

140 - 159

OR

90 – 99

Stage2 Hypertension

≥ 160

OR

≥ 100

If the systolic and diastolic blood pressure measurements fall into two
different categories, the blood pressure classification is the higher of the two
categories.

•

Source: The Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure.
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Table 1.5 Putative Mechanisms of Obesity-Related Hypertension
Possible underlying
mechanisms

Primary mechanisms

Anti-natriuretic effect of insulin
Increased renal SNS activity
Sodium retention

Increased aldosterone
Increased cortisol activity
Anatomic renal compression
Insulin resistance
Renin-angiotensin
Leptin/other adipokines

Increased SNS activity

Obstructive sleep apnea

(SNS, sympathetic nervous system)

Adrenergic receptor
polymorphisms
Psychological stress
Increased circulating renin-angiotensin

Increased renal SNS activity

Increased adipose renin-angiotensin
Impaired vascular endothelial function

Insulin resistance
Insulin resistance

Other vascular mechanisms
Altered vascular ion transport
•

Adapted from Theodore A. Kotchen, 2010.
Hypertension, Ltd.
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© 2010 American Journal of

Table 1.6 Prevalence of Hypertension in Age-Matched Adult Men and
Women

•

Age

Men (%)

Women (%)

20 - 34

9.2

2.2

35 - 44

21.1

12.6

45 - 54

36.2

36.2

55 - 64

50.2

54.4

65 - 74

64.1

70.8

≥ 75

65.0

80.2

All

31.8

30.3

Source: National Center for Health Statistics. Health, United States, 2008
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Table 1.7 Estrogen Regulation of RAS Components
RAS

Species

Intervention

Site/cell line

Changes

References

Human

Estrogen/

Plasma

+

[190-196]

(Female)

pregnancy/

-

[196, 197]

Plasma

+

[198-203]

Liver

+

[200, 201,

(Gender)
Agt

contraceptives/
ERT
Menopause
Rat

Estrogen

204-206]
Brain

Kidney

+

[207, 208]

-

[209]

+

[203, 205,
206]

Renin

Human

Estrogen/

(Female)

pregnancy/

Aorta

+

[206]

Plasma

+

[192, 210]

-

[196, 211,

contraceptives
Rat
ACE

212]

Estrogen

+

[198, 199]

Human

Estrogen/ERT

Serum

-

[196, 213]

Rat

Estrogen/ERT

Plasma/

-

[214, 215]

Heart

-

[141]

Lung

-

[215]

Kidney

-

[215]

Endothelial

-

[216]

-

[217]

Serum

AT1R

Human

Estrogen

progenitor
cells (EPCs)
Rat

Estrogen

Aorta
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ACE2

Rat

Adrenal

-

[218]

Kidney

-

[142, 143]

Ovariectomy

Kidney

-

[144, 145]

Pregnancy

Kidney

+

[146, 147]

Reproductive

+

[146, 147]

Adipose

-

[53]

Kidney

==

[53]

3T3-L1 cell

+

[53]

Adipose

+

[219]

organs
Mouse

Ovariectomy

Estrogen
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Figure1.1 The Renin-Angiotensin System (RAS)
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Figure 1.2 Ang-(1-7) signaling in cardiomyocytes. Ang-(1-7) activates the PI3K/AKT/NOS3 pathway leading to NO generation and cGMP production.
Activation of this pathway culminates with inhibition of Ang II-induced NFAT
translocation. Preliminary evidence suggests that NOS1 expression may be
modulated by Ang-(1-7). Ang-(1-7) also inhibits ET-1 and FBS activation of cell
growth.

The

consequences

of

Ang-(1-7)/Mas

and

B2R

cross-talk

for

cardiomyocyte function are still unknown (?). →= activation; - -= inhibition; ET-1 =
endothelin; Ang II = angiotensin II; Ang-(1-7) = angiotensin-(1-7); ET-R =
endothelin receptor; AT1-R = AT1 receptor; Mas = Mas receptor; B2R =
bradykinin receptor type 2; FBS = fetal bovine serum; NFAT = nuclear factor of
activated

T

cells;

GSK3β =

glycogen

synthase

kinase

3β;

PI3-K

=

phosphatidylinositol 3-kinase; AKT = protein kinase B; NOS3 = nitric oxide
synthase 3; NOS1 = nitric oxide synthase 1; NO = nitric oxide; cGMP = cyclic
guanosine monophosphate; ERK 1/2 = extracellular signal regulated kinase 1/2.
The question marks denote areas in which the current state of knowledge is still
preliminary. Adapted from Enéas et al. International Journal of Hypertension,
2012.
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Figure 1.3 Role of ACE2–Ang-(1–7)–Mas axis in vascular function and
redox signaling in vessels. Under normal physiological conditions (a), •NO
exerts pleiotropic effects in the regulation of vascular function. The balance
between levels of •O2 − and released •NO has a critical role in the maintenance
of normal endothelial function. However, in pathological conditions (b),
excessive •O2 −,

mainly

produced

by

NAD(P)H

oxidase,

stimulates

vasoconstriction and inflammation, resulting in endothelial dysfunction, mainly
through the reduction of •NO bioavailability and the imbalance between ROS and
antioxidant capacity. Thus, the classic RAAS is a potent prooxidant system in
vessels, causing endothelial dysfunction. The ACE2–Ang-(1–7)–Mas axis
counteracts these effects. For more details, see text. AT1-R, angiotensin type I
receptor; Cat, catalase; COX, cyclooxygenase; GPX, glutathione peroxidase; EcSOD; extracellular-superoxide dismutase; LPO, lipid peroxidation; MPO,
myeloperoxidase; XO, xanthine oxidase. Adapted from Luiza A Rabelo et al.
Hypertension Research 34, 154-160 (February 2011) | doi:10.1038/hr.2010.235
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STATEMENT OF THE PROBLEM
The prevalence of both obesity and hypertension are rising in the United
States. In studies examining the prevalence of hypertension between NHANES
III (1988-1994) and NHANES 1999-2004, hypertension prevalence increased
from 24.4 to 28.9%. A rise in the body mass index has been suggested to be the
primary factor contributing to the rising prevalence of hypertension in males.
Surprisingly, the increase of hypertension prevalence was even greater in
women (from 23.3 to 28.8%) than men (from 25.3 to 28.5%). In general, women
are thought to be protected from developing hypertension before menopause, but
after menopause the prevalence of hypertension in females exceeds that of agematched males. Since females experience a high prevalence of obesity, and
obesity is a common problem facing post-menopausal females, understanding of
the role of obesity in the rising prevalence of hypertension in females is
significant. Moreover, despite the high prevalence of individuals both overweight
and obese in the US, very few studies have focused on mechanisms contributing
to sex differences in the development of obesity-hypertension in males versus
females. Thus, examination of protective mechanisms in pre-menopausal
females as compared to contributory mechanisms in males may help to uncover
novel therapeutic targets for hypertension.
An activated renin-angiotensin system (RAS) has been suggested to
contribute to the development of obesity-induced hypertension in humans and
experimental animals. Results from our laboratory suggest that an activated
adipocyte renin-angiotensin system (RAS) may be a link between obesity and
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hypertension. We have recently demonstrated that adipose tissue can serve as a
predominant source of systemic angiotensin II (AngII) in obese male
hypertensive mice. We also demonstrated that adipocytes express angiotensin
converting enzyme 2 (ACE2). ACE2 cleaves AngII to form the vasodilator
peptide, angiotensin-(1-7) (Ang-(1-7)), which exerts its effects through the mas
receptor (MasR). Since the effects of Ang-(1-7) generally counteract those of
AngII, the ACE2/Ang-(1-7)/MasR axis is thought of as the counter-regulatory arm
of the RAS.

In male obese hypertensive mice exhibiting increased adipose-

derived systemic AngII, adipose ACE2 expression was reduced and systemic
Ang-(1-7) concentrations plummeted to levels of an ACE2 knockout. These
results suggest that reductions in ACE2 in an expanded adipose mass make
AngII the predominant adipose-derived RAS peptide, contributing to hypertension
in obese male mice. In contrast, obese female mice were resistant to the
development of hypertension despite greater adiposity. Remarkably, in contrast
to obese hypertensive males, female normotensive obese mice exhibited
increased adipose ACE2 activity associated with elevated plasma Ang-(1-7)
concentrations. Deficiency of ACE2 converted obese females to a hypertensive
phenotype. In addition, removal of ovarian sex hormones by ovariectomy (Ovx)
reduced adipose ACE2 activity and plasma Ang-(1-7) concentrations and
resulted in robust obesity-induced hypertension. These results suggest that an
ACE2-related, sex hormone-dependent mechanism in adipose tissue contributes
to the resistance of females to obesity–hypertension.

Further, a lack of this

protective mechanism may be responsible for the increased susceptibility to
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obesity-induced hypertension in male mice. While these studies were the first to
illustrate potential mechanisms contributing to sexual dimorphism of obesityhypertension, there remained several unanswered questions.

Specifically, is

estrogen the sex hormone regulating adipose ACE2 to protect females from
obesity-hypertension? Second, does ACE2 influence obesity-hypertension
through effects of Ang-(1-7) at Mas receptors (MasR)?
The central hypothesis of these studies is that estrogen-mediated regulation
of ACE2 influences the AngII/Ang-(1-7) balance and thereby contributes to sex
differences in the development of obesity-hypertension. In a mouse model of
high fat (HF) diet-induced obesity, we investigated the role of two components of
the counter-regulatory axis of the RAS to define mechanisms for sexual
dimorphism of obesity-hypertension: ACE2 (Aim 1) and MasR (Aim 2).
Specifically, in Aim 1 we defined the effects of estrogen to restore protection of
Ovx female mice from obesity-hypertension, and therapeutically protect male
mice from obesity-induced hypertension. Studies under this aim were designed
to test the hypothesis that estrogen-mediated increases in adipose ACE2 reduce
the

AngII/Ang-(1-7)

balance

and

protect

females

from obesity-induced

hypertension. In Aim 2, we defined the role of MasR deficiency on the
development of obesity and hypertension in male and female mice. Studies
under this aim were designed to test the hypothesis that MasR deficiency (1)
abolishes protection of female HF-fed mice from the development of obesityhypertension, and (2) augments obesity- hypertension in male mice.
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Section II. SPECIFIC AIM 1
2.1 Summary
We recently demonstrated that female mice are resistant to the development
of obesity-induced hypertension through a sex hormone-dependent mechanism
that involved adipose angiotensin-converting enzyme 2 (ACE2). In this study, we
hypothesized that provision of 17β-estradiol (E2) to ovariectomized (OVX) highfat (HF)-fed female hypertensive mice would reverse obesity-hypertension
through an ACE2-dependent mechanism. Pilot studies defined dose-dependent
effects of E2 in OVX female mice on serum E2 concentrations and uterine
weights. An E2 dose of 36 μg/ml restored normal serum E2 concentrations and
uterine weights. Therefore, HF-fed OVX female Ace2+/+ and Ace2−/− mice were
administered vehicle or E2 (36 μg/ml) for 16 weeks. Serum E2 concentrations
were significantly increased with E2 administration in HF-fed OVX females of
both genotypes. E2 administration significantly decreased body weights of HFfed OVX female Ace2+/+ and Ace2−/− mice of either genotype, suggesting an
ACE2-independent role

of

E2 on

energy

metabolisms. At

15

weeks,

E2 administration decreased systolic blood pressure (SBP) of OVX HFfed Ace2+/+ but not Ace2−/− females during the light but not the dark cycle or
averaged 24 hour period. Interestingly, E2 administration significantly increased
heart rate and physical activity (dark cycle) in HF-fed Ace2+/+ but not
in Ace2−/− OVX females. E2-mediated reductions in SBP in Ace2+/+ females were
associated with significant elevations in adipose ACE2 mRNA abundance and
activity and reduced plasma angiotensin II (AngII) concentrations. In contrast to
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females, E2 administration had no effect on any parameter quantified in HF-fed
male hypertensive mice. In 3T3-L1 adipocytes, E2 promoted ACE2 mRNA
abundance through effects at estrogen receptor-α (ERα) and resulted in ERαmediated

binding

at

the

ACE2

promoter.

These

results

demonstrate

that E2 administration to OVX females reduces obesity-induced elevations in
SBP (light cycle) through an ACE2-dependent mechanism. Beneficial effects of
E2 to decrease blood pressure in OVX obese females may result from stimulation
of adipose ACE2.
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2.2 Introduction
The prevalence of hypertension has consistently risen in the United States
largely due to the increasing prevalence of obesity. Data from the most recent
National Health and Nutrition Examination Survey (NHANES) demonstrate that
the prevalence of hypertension is rising at a faster rate in females than males [7].
It is generally well accepted based on data from cross-sectional studies that adult
males are at a higher risk to develop hypertension than females until after
menopause, when female prevalence of both obesity and hypertension increases
markedly [220, 221]. Mechanisms for the role of menopause in the increasing
prevalence of hypertension in females, or for the faster rise in hypertension
prevalence in females compared to males are unclear.
An activated renin-angiotensin system (RAS) has been suggested to
contribute to the development of experimental and human obesity-induced
hypertension [76, 122, 222, 223]. Indeed, recent studies from our laboratory
demonstrate that adipose tissue serves as a predominant source for elevated
systemic concentrations of angiotensin II (AngII) and the development of
hypertension in male obese mice [95]. Adipocytes express several components
of the RAS necessary to synthesize, respond to, or metabolize AngII. In male
mice with diet-induced obesity-hypertension associated with increased plasma
and adipose AngII concentrations, adipose expression of angiotensin converting
enzyme 2 (ACE2) [122], which metabolizes AngII to form angiotensin-(1-7) (Ang(1-7)), was reduced and plasma Ang-(1-7) concentrations plummeted to levels of
ACE2 deficient mice [53].

In contrast, female mice made obese from
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consumption of a high fat (HF) diet did not exhibit changes in plasma AngII
concentrations and were resistant to the development of obesity-induced
hypertension [53]. Moreover, protection against obesity-hypertension in females
was associated with increased adipose ACE2 expression and elevated plasma
concentrations of the vasodilator, Ang-(1-7) [53]. Ovariectomy of HF-fed female
mice reduced adipose ACE2 expression and plasma Ang-(1-7) concentrations
and converted female mice to an obesity-hypertension phenotype [53]. These
results suggest that sexual dimorphism of obesity-hypertension may be
associated with ACE2-mediated regulation of the AngII/Ang-(1-7) balance, and
that adipose ACE2 may contribute significantly to regulation of the balance of
these vasoactive peptides.
17β-Estradiol (E2) has been reported to regulate ACE2 expression both in
vitro and in vivo [53, 145, 147]. Moreover, results from our laboratory
demonstrated that E2 increases ACE2 mRNA abundance in adipocytes [53]. In
this study, we hypothesized that ovariectomy promotes obesity-induced
hypertension in females through an E2-mediated mechanism. In addition, we
hypothesized that E2 administration to ovariectomized (Ovx) HF-fed females
protects against obesity-hypertension through an ACE2-dependent mechanism.
To determine if exogenous E2 can also prevent the development of obesityhypertension in males, we administered E2 to HF-fed wild type and ACE2
deficient male mice. Finally, to explore mechanisms of E2 regulation of adipose
ACE2, we defined the estrogen receptor (ER) responsible for E2-mediated
regulation of ACE2 mRNA abundance in 3T3-L1 adipocytes, and demonstrated
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direct interaction between ERα and the ACE2 promoter in adipocytes exposed to
E2.
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2.3 Materials and Methods
2.3.1 Animal Handling
All studies using mice were approved by an Institutional Animal Review
Committee at the University of Kentucky and were conducted in accordance with
the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals. In pilot studies to determine the optimal E2 dose to activate adipose
ACE2, wild type female mice (C57BL/6, 8 weeks age) underwent ovariectomy
and then 2 weeks later (to clear endogenous sex hormones) mice were assigned
to groups to receive E2 (0, 36, 200 or 600μg/ml, n=5 mice/group) via silastic
tubing capsules for one month; a group of intact female mice (n=5) without drug
treatment were included for comparison. At study end point, mice were
anesthetized with IP ketamine/xylazine (100/10 mg/kg, intraperitoneal) for
exsanguination and tissue harvest.
In a separate study, female mice underwent ovariectomy as described
previously [53], followed by a two week interval to clear endogenous sex
hormones prior to the onset of HF feeding (ad libitum; 60% kcal as fat; D12492,
Research Diets Inc.). Male and female wild type (Ace2+/y, n=20 mice; Ace2+/+,
n=20 mice, respectively) or whole body ACE2 deficient mice (Ace2-/y, n=20 mice;
Ace2-/-, n=20 mice, respectively; 2 months of age; backcrossed 10x onto a
C57BL/6 background) were fed the HF diet for 16 weeks. Silastic tubing inserts
were filled with vehicle (sesame oil; Sigma-Aldrich, St. Louis, MO) or E2 (17-β
estradiol, 36μg/ml [224], equivalent to a dose of 1.2µg/kg/d, Sigma, St. Louis,
MO)) and implanted subcutaneously into the interscapular space of anesthetized
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mice (vehicle group, n=8 mice/genotype; E2 group, n=12 mice/genotype) for
sustained delivery at the onset of HF feeding. Each month, empty silastic tubing
capsules were removed from anesthetized mice and replaced with tubing
containing fresh drug. At study endpoint, body composition was quantified in
conscious mice by echo-MRI. At study endpoint, mice were anesthetized with
ketamine/ xylazine (100/10 mg/kg, intraperitoneal) for exsanguination and tissue
harvest.
2.3.2 Quantification of Plasma Parameters
Plasma concentrations of AngII in HF fed male and female mice were
quantified as described previously [225]. Plasma renin concentrations were
quantified as described previously [95]. Serum E2 concentrations were quantified
using a commercial estradiol ELISA kit (Calbiotech, ES180S-100) following the
manufacturer’s instructions.
2.3.3 Quantification of Blood Pressure
Blood pressure was quantified by radiotelemetry at week 16 of HF feeding as
described previously [122].

Briefly, at week 15 of HF feeding, anesthetized

(isoflurane to effect) mice were implanted with left carotid artery catheters
followed by a one week recovery, and then blood pressure was recorded
(sampling every 5 minutes) for 5 consecutive days.
2.3.4 Tissue RNA extraction and quantitative RT-PCR
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Tissue RNA was isolated using the SV Total RNA Isolation system (Promega,
Madison, WI). RNA concentrations were then determined using a NanoDrop
2000 spectrophotometer (Thermo Scientific, Wilmington, DE); 400 ng of RNA
was used for reverse transcription to make cDNA using a Retroscript kit. cDNAs
were amplified using SYBR Green PCR Master Mix(Quanta, Gaithersburg, MD ).
Estimation of amplified gene products was normalized to 18s RNA. Primer
sequences

used

are

as

follows:

ACE2:

forward:

5’-

ACGAGATGGGACACATCCA-3’, reverse: 5’-GAAAATCGGATGGCAGAAGA-3’.
18s:

forward:

5’-AGTCGGCATCGTTTATGGTC-3’

CGAAAGCATTTGCCAAGAAT-3’.

ERα:

TCTCTGGAAGAGAAGGACCACATC-3’,

reverse:
forward:

reverse:

5’5’5’-

TGCAGAGTCAGGCCAGCTTT-3’. ERβ: forward: 5’-GACACCTCTCTCCTTTAG3’, reverse: 5’-CAGGGTCTCTCTGTTTAC-3’
2.3.5 Quantification of Tissue ACE2 Activity
Mca-APK(Dnp)(BML-P163-0001), a fluorogenic substrate for ACE2 was
purchased from Enzo Life Sciences, Farmingdale, NY. Adipose tissue and kidney
samples were homogenized in ACE2 buffer (0.1 M Tris-HCl, 0.3M NaCl, 10 μM
ZnCl2 Z-pro-prolinol with protease inhibitors (Roche, cOmplete ULTRA Tablets,
0.5% Triton X-100; pH 7.0) using Geno/Grinder 2010 for protein extraction. Total
protein extracts (kidney, 10µg; adipose tissue, 100µg) were incubated with ACE2
reaction buffer (75 mM Tris-HCl, 1M NaCl, 0.5 mM ZnCl2, 100 μM Z-pro-prolinol,
10 μM captopril; pH 7.0) and the intramolecularly quenched synthetic ACE2specific substrate Mca-APK(Dnp) in black 96 well plates (100 μL total volume).
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ACE2 activity was quantified by fluorescence (read at excitation of 320 nm and
emission at 405 nm, auto cutoff at 420 nm). For adipose tissue, protein extracts
were incubated with 25 μM Mca-APK(Dnp) for 2.5 hours at 37°C; for kidney,
protein extracts were incubated with 10 μM Mca-APK(Dnp) for 1 hour at 37°C.
Preliminary studies defined conditions where the ACE2 substrate concentration
and time of incubation were not limiting. Total fluorescence was corrected for
protein content (in kidney and adipose tissue homogenates) after subtracting
blank values. ACE2 activity is expressed as relative fluorescence unit per µg
protein per hour (RFU/µg/hr).
2.3.6 In vitro effect of E2 on ACE2 mRNA abundance in 3T3-L1
adipocytes
3T3-L1 cells from ATCC were cultured and differentiated according to the
manufacturer’s standard protocol with modification. Briefly, cells were seeded
and cultured in 6-well plates in regular DMEM containing 10% new born calf
serum (NCS) and 1% Pen/Strep). At 2 days post confluence, cells were
incubated with an adipocyte differentiation cocktail (regular DMEM with 10% fetal
bovine serum, 1% Pen/Strep, 0.2 µM insulin, 0.5 mM IBMX and 1.0 µM
Dexamethasone) for 2 days. On day 3, cells were incubated with Adipocyte
Maintenance Medium (regular DMEM with 10% FBS, 1% Pen/Strep and 0.2 µM
insulin) for 2 days. Cells were than maintained in phenol red free DMEM with
10% regular FBS until treatment. On day 8, mature adipocytes were serumstarved with 1% Charcoal stripped FBS (Gibco, Life Technologies) and incubated
with vehicle (0.001% DMSO, ATCC, Manassas, VA) or E2 (100 nM) with or
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without an ERα antagonist (MPPD, 100 nM, Tocris Bioscience, Bristol, UK) for 24
hours. At study endpoint, cells were washed with ice cold PBS and harvested in
0.5 mL TRIzol (Ambion, NY) for RNA extraction.
2.3.7 Chromatin Immunoprecipitation (ChIP) in 3T3-L1 Adipocytes.
We performed ChIP in 3T3-L1 adipocytes using a commercial Simple ChIP
Enzymatic Chromatin IP kit (Cell Signaling Technology, Massachusetts) following
the manufacturer’s instructions and using an ERα antibody (rabbit polyclonal,
HC-20X, Santa Cruz). Briefly, 3T3-L1 cells were seeded and differentiated in
150mm culture dishes and differentiated to mature adipocytes as described
above. On day 8, adipocytes were serum-starved with 1% Charcoal stripped FBS
(Gibco, Life Technologies) and incubated with vehicle (0.001% DMSO, ATCC,
Manassas, VA) or E2 (100 nM) for 1 or 12 hours. Cells (2-3 dishes, 4X107 cells
for each experiment to achieve appropriate starting material) were cross-linked
and harvested for nuclei preparation and chromatin digestion following the
manufacturer’s protocol. After chromatin digestion, we determined DNA fragment
size and concentration to optimize the assay.

ERα antibody (10 µg) was

incubated with chromatin (containing 20µg DNA) overnight at 4°C with rotation.
The use of control antibodies were strictly according to the manufacturer’s
protocol. Input chromatin (2%) as well as immunoprecipitated chromatin were
reverse cross-linked and purified for RT-PCR. The primer set used to amplify the
putative ERE site (5’- AGGTCAAACTCTCTG- 3’) of the ACE2 promotor region is
ACE2P2:

forward:

AGCATCAAGGTCAAACTCTCTG,

reverse:

AAAGGACCCTCTAGAGATGGAG (product size, 201bp). PCR signals were
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normalized to signals of 2% input sample, and were expressed as signal relative
to input.
2.3.8 Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were performed
using SigmaStat (SPSS). For 2 factor analysis, a two-way ANOVA (genotype and
treatment as between group factors, time as a repeated measure when
applicable) was used to analyze end-point measurements followed by HolmSidac for post hoc analyses. Values of P < 0.05 were considered to be
statistically significant.
2.4 Results
2.4.1 A low dose of E2 administered to Ovx female mice restores plasma
E2 concentrations to levels of ovary intact females
To determine a dose of E2 that would restore plasma E2 concentrations to
physiologic levels in Ovx females, E2 (36, 200 or 600 µg/ml, equivalent to 1.2,
6.7, or 20 µg/kg/day) was administered to female Ovx mice for 1 month. Normal
physiological E2 concentrations were determined using serum samples from
ovary intact female mice.

Plasma E2 concentrations were significantly

decreased at 1 month of ovariectomy compared to intact female controls (Figure
2.1A; P<0.05). The lowest dose of E2 (36 µg/ml) restored serum E2
concentrations to levels that were not significantly different from intact females
(Figure 2.1A). Higher E2 doses resulted in a modest dose-dependent increase in
serum E2 concentrations. We quantified uterine weight as a second measure of
64

physiologic E2 concentrations, which was reduced significantly in Ovx females
compared to controls (Figure 2.1B; P<0.05). The lowest dose of E2 restored
uterine weight to the levels of ovary intact female controls, while higher E2 doses
resulted in supra-physiologic increases in uterine weight (Figure 2.1B; P<0.05).
We also administered E2 at the highest dose (600 μg/mL) to intact male mice
that resulted in a significant reduction in male sex organ weights (control: 0.63 ±
0.02g, E2: 0.57 ± 0.02g, P<0.05). Based on these results, we chose to administer
E2 (36 µg/ml) to HF-fed Ovx female and male mice.
2.4.2 E2 administration reduces SBP during the light, but not the dark
cycle in Ace2+/+, but not in Ace2-/- Ovx female mice, and has no effect
on obesity-induced hypertension in male mice.
Female Ovx mice exhibited significant increases in body weight with HF
feeding, with no significant differences between genotypes (Figure 2.2A; P>0.05).
E2 administration significantly decreased body weight (Figure 2.2A; P<0.05) and
fat mass (Figure 2.2B; P<0.05) in Ace2+/+ and Ace2-/- female Ovx mice, with no
significant differences between genotypes. Moreover, E2 administration resulted
in a significant increase in serum E2 concentrations in HF-fed Ovx females of
both genotypes (Table 2.1). Heart weight was significantly increased, while
plasma renin concentrations were significantly decreased in HF-fed Ace2-/- Ovx
females compared to Ace2+/+ controls, regardless of treatment group (Table 2.1;
P<0.05).
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We quantified plasma AngII concentrations, ACE2 activity and ACE2 mRNA
abundance in adipose tissue and kidneys from HF-fed female Ovx Ace2+/+ and
Ace2-/- mice. Plasma AngII concentrations were significantly decreased in HF-fed
Ace2-/- female Ovx mice compared to Ace2+/+ controls (vehicle groups; Figure
2.3A; P<0.05). Moreover, E2 administration significantly decreased plasma AngII
concentrations in HF-fed Ace2+/+, but not in Ace2-/- Ovx females (Figure 2.3A;
P<0.05). Consistent with E2-mediated reductions in plasma AngII concentrations
in HF-fed Ovx Ace2+/+ females, E2 administration significantly increased ACE2
mRNA abundance (Figure 2.3B; P<0.05) and ACE2 activity (Figure 2.3C;
P<0.05) in adipose tissue from Ace2+/+, but not Ace2-/- females. In contrast to
adipose tissue, E2 administration had no effect on ACE2 mRNA abundance
(Figure 2.4A), but significantly reduced ACE2 activity in kidneys from HF-fed
Ace2+/+ Ovx females (Figure 2.4B; P<0.05). There was reduced ACE2 mRNA
abundance and activity in kidneys and adipose tissue from female ACE2
deficient mice (Figure 2.3, 2.4).
E2 administration significantly decreased SBP during the light, but not during
the dark cycle in HF-fed Ace2+/+ Ovx females (Figure 2.5A, B; P<0.05). However,
E2 administration had no effect on SBP (light or dark cycle) in Ace2-/- Ovx
females (Figure 2.5A, B; P>0.05).

When averaged over 24 hours, E2

administration had no significant effect on SBP in HF-fed Ace2+/+ or Ace2-/- Ovx
females (Figure 2.5C, Table 2.1; P>0.05). In addition, E2 administration
significantly reduced MAP during the light cycle, but not the dark cycle in HF-fed
Ace2+/+, but not in Ace2-/- Ovx females (Table 2.1; P<0.05). Interestingly, E2
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administration significantly increased heart rate and physical activity (dark cycle)
in HF-fed Ace2+/+, but not in Ace2-/- Ovx females (Table 2.1; P<0.05). In contrast
to females, E2 administration had no effect on any parameter quantified in HFfed Ace2+/y or Ace2-/y male mice (Figure 2.6, 2.7; Table 2.2).
2.4.3 E2 promotes ACE2 mRNA abundance in 3T3-L1 adipocytes by
eliciting ERα-mediated binding to the ACE2 promoter.
Administration of E2 to HF-fed Ovx females promoted ACE2 mRNA
abundance and activity in adipose tissue, but not in kidney, in a manner
consistent with E2-mediated protection against obesity-hypertension. We
quantified relative mRNA abundance of ERα and ERβ mRNA in adipose tissue
from HF-fed Ace2+/+ Ovx females administered vehicle. ERα mRNA abundance
was >150-fold greater than ERβ in adipose tissue from obese females (Figure
2.8A; P<0.05). Moreover, E2 administration significantly increased ERα mRNA
abundance in adipose tissue of HF-fed Ovx females compared to vehicle controls
in both genotypes (Figure 2.8B; P<0.05). We used 3T3-L1 adipocytes to define
mechanisms for E2-mediated regulation of ACE2. As previously demonstrated
[53], E2 (100 nM) stimulated ACE2 mRNA abundance in 3T3-L1 adipocytes, and
these effects were abolished by an ERα (MPPD) antagonist (Figure 2.9A;
P<0.05). To explore mechanisms for E2-mediated regulation of adipocyte ACE2,
we performed a ChIP assay in 3T3-L1 adipocytes incubated with vehicle or E2
(100 nM) for 1 or 12 hours followed by immunoprecipitation with an ERα antibody
and RT-PCR. Following 12 hours incubation with E2, there was a two-fold
enrichment of ERα binding to a putative estrogen response element (ERE, 5’67

AGGTCAAACTCTCTG- 3’) in the ACE2 promoter region (Figure 2.9B) and PCR
product size (201 bp) corresponded to the amplified promoter region of ACE2
(Figure 2.9C).
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2.5 Discussion
The results of this study demonstrate that E2 administration exhibits
beneficial effects on the development of obesity-induced hypertension in female
Ovx mice through an ACE2-dependent mechanism. The major findings of the
present study are (1) E2 administration stimulates adipose ACE2 mRNA
abundance and activity in HF-fed Ovx females, (2) E2 administration lowers
plasma AngII concentrations in HF-fed Ovx females, (3) these effects most likely
contribute to reductions in blood pressure of HF-fed Ovx females administered
E2 and (4) E2 administration reduces blood pressure during the light, but not the
dark cycle of HF-fed females. These effects were not observed in ACE2 deficient
obese female mice, supporting an ACE2-dependent mechanism of E2 action.
Moreover, beneficial effects of E2 administration at a dose that in preliminary
studies physiologically restored serum E2 concentrations and uterine weights of
Ovx females to normal levels, had no effect on blood pressure when
administered to male obese mice. These results demonstrate that effects of
ovariectomy to promote hypertension in obese female mice likely involve a lack
of endogenous E2. Moreover, these results demonstrate that E2 exhibits
protective effects to reduce SBP (light cycle) in females through an ACE2dependent mechanism.

Finally, effects of E2 to promote ACE2 mRNA

abundance and activity were evident in adipose tissue, but not in kidneys of
obese female hypertensive Ovx mice. In addition, E2 promoted ACE2 mRNA
abundance through direct interaction at the ACE2 promoter in 3T3-L1
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adipocytes. These results suggest that adipose tissue may be a target of E2 to
stimulate ACE2 and protect females from obesity-hypertension.
Cross sectional [140, 226], but not longitudinal studies [227] indicate
menopause as a hallmark of increased hypertension prevalence in adult females.
Postmenopausal women not only have higher systolic blood pressures (4-5
mmHg) compared to premenopausal women [228], but also the prevalence of
hypertension and the rate of increase in postmenopausal women is higher than
that observed in premenopausal women [7, 140].

Observations performed

during the menstrual cycle [229, 230] and early pregnancy [231] suggest an
inverse correlation between endogenous E2 levels and female arterial blood
pressure. It is generally well accepted that the prevalence of obesity also
increases in postmenopausal women [140, 228], most likely due to reductions in
local or systemic E2 concentrations. Our results extend previous findings related
to sexual dimorphism of hypertension to the setting of obesity, and demonstrate
that ovariectomy, a form of castration-induced menopause in mice, promotes the
development of obesity-induced hypertension through an E2-dependent
mechanism. An extension of these findings is that endogenous E2 may protect
against the development of hypertension in premenopausal obese females, while
a lack of E2 in postmenopausal females may contribute to the rising prevalence
of both obesity and hypertension in this population.
Estrogen has been reported to exert beneficial effects to lower blood pressure
through suppression of the expression of several components of the RAS
necessary to synthesize or respond to AngII [141, 217]. In addition, studies have
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demonstrated that E2 positively regulates the expression of ACE2, an enzyme
that also suppresses the RAS, and the effect of E2 may be attributed to estrogen
receptor action at two putative estrogen response elements on the ACE2
promoter [232]. Indeed, we previously demonstrated that E2 promoted mRNA
abundance of ACE2 in 3T3-L1 adipocytes [53]. Results from this study extend
previous findings by demonstrating that E2 stimulates ACE2 mRNA in 3T3-L1
adipocytes through ERα-mediated signaling, as demonstrated through blockade
of E2-mediated regulation of ACE2 by an ERα antagonist.

Moreover, ChIP

results reveal the interaction of ERα with a putative ERE on the ACE2 promoter.
We previously demonstrated that female mice do not exhibit an increase in
blood pressure when fed a HF diet compared to low fat-fed controls, and that
these effects were reversed by ovariectomy [53]. Results from this study extend
previous findings by demonstrating that effects of ovariectomy to promote an
obesity-hypertension

phenotype

are

at

least

partially

reversed

administration in wild type, but not in ACE2 deficient females.

by

E2

Interestingly,

effects of E2 to stimulate ACE2 were present in adipose tissue, but not in kidneys
from obese females, suggesting as has been previously described that E2
regulates ACE2 in a tissue-specific manner [233]. Moreover, since beneficial
effects of E2 to lower blood pressure were absent in HF-fed ACE2 deficient
females, these results demonstrate that E2 acts through an ACE2-dependent
mechanism. It is unclear why the blood pressure lowering effect of E2 was seen
during the light phase (resting phase), but not during the dark phase (active
phase). However, E2 administration stimulated physical activity [234] and heart
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rate in Ace2+/+ obese Ovx females during the dark, but not the light cycle. This
stimulatory effect of E2 during the dark cycle may have masked its ability to
decrease blood pressure. It is also unclear from the present studies if beneficial
effects of E2 to promote adipose ACE2 expression are directly responsible for
the observed reductions in plasma AngII concentrations and blood pressure of
female Ovx mice. Future studies should address the role of adipocyte ACE2 in
the development of obesity-induced hypertension in male and female mice.
An extension of these findings to the clinical setting would include potential
administration of E2 to post-menopausal hypertensive females. However, the
feasibility of using E2 therapeutically to treat hypertension in females (obese
and/or postmenopausal) has been limited due to its carcinogenic properties as
well as potential worsening cardiovascular outcomes reported in several
controlled clinical trials [235-237]. Indeed, several studies in humans and animal
models assessing the effects of estrogen on blood pressure have yielded mixed
results [196, 238-243]. Our results suggest that the dose of E2 may be a critical
determinant of its efficacy to lower blood pressure. We used a dose of E2 that in
preliminary studies restored physiologic plasma E2 concentrations and uterine
weights of Ovx females, and that in obese Ovx females resulted in a significant
increase in plasma E2 concentrations. Moreover, this dose of E2 activated
adipose ACE2 and reduced plasma AngII concentrations in obese Ovx females,
most likely contributing to observed reductions in obesity-induced hypertension.
An interesting finding of the present study was the lack of effect of E2
administration to protect male mice from obesity-induced hypertension. These
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results suggest that male mice do not express sufficient levels of estrogen
receptors in relevant tissues to respond to exogenous E2 (e.g., adipose), or may
require increased doses of E2 to lower blood pressure. We did not pursue
administration of higher E2 doses to obese male mice, as this would not be a
viable therapeutic option in humans due to a variety of ancillary properties of the
sex hormone.
While administration of E2 to Ovx HF-fed females reduced SBP (light cycle) in
the present study, it also resulted in less weight gain, which could have
contributed to the efficacy of E2 to prevent obesity-induced hypertension.
Indeed, administration of E2 to HF-fed female mice has been previously reported
to blunt the development of obesity [244, 245]. In this study, E2-mediated
reductions in body weight were observed in Ovx HF-fed wild type females as well
as in females with whole body ACE2 deficiency. However, only wild type Ovx
females exhibited reductions in blood pressure following E2 administration. Thus,
it is unlikely that E2-mediated reductions in body weight serve as the primary
mechanism contributing to E2-mediated reductions in SBP in Ovx females.
In conclusion, results from this study demonstrate that administration of E2 to
Ovx females reduced SBP during the light, but not the dark cycle, blunting the
development of obesity-induced hypertension. Moreover, as effects of E2 to
activate adipose ACE2, reduce plasma AngII concentrations, and decrease blood
pressure were not evident in ACE2 deficient obese females, these results
suggest that E2-mediated reductions in SBP are ACE2-dependent. Finally, our
results demonstrate direct effects of E2 to promote ACE2 expression in
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adipocytes through interactions with ERE on the ACE2 promoter. These results
suggest that low dose E2 may afford protection against obesity-hypertension in
post-menopausal females.
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Table 2.1 Characteristics and radiotelemetry parameters of HF-fed Ovx
female wild type and ACE2 deficient mice administered vehicle or E2.
Ovx female
Ace2

mice

+/+

Vehicle
Body

-/-

Ace2
E2

Vehicle

E2

49.4 ± 2.0

36.9 ± 2.0*

48.9 ± 2.8

38.8 ± 2.3*

Fat mass (g)

26 ± 1.2

15.1 ± 1.7*

23.5 ± 2.8

16.8 ± 1.8*

Lean mass (g)

21.5 ± 0.7

20.1 ± 0.5

20.9 ± 1.3

20.0 ± 0.4

0.16 ± 0.01

0.16 ± 0.01

0.18 ± 0.01#

0.18 ± 0.01#

0.030±0.004

0.055±0.006*

0.019±0.001

0.058±0.006*

3.37 ± 0.14

4.75 ± 0.32*

3.43 ± 0.48

4.03 ± 0.36*

464.0±141.0

124.4±49.3*

158.4±55.3

1.59 ± 0.37

2.08 ± 0.41

0.69 ± 0.24

619 ± 11

665 ± 9*

646 ± 15

661 ± 12

37.3 ± 1.2

35.6 ± 1.0

43.2 ± 1.5

41.3 ± 1.3

Light cycle

113.1 ± 0.5

107.6 ± 1.5*

110.3 ± 3.2

108.0 ± 1.6

Dark cycle

122.3 ± 1.3

121.2 ± 1.4

123.1 ± 4.6

121.3 ± 2.2

weight (g)

Heart
weight (g)
Uterine
weight (g)
Serum
E2 (pg/mL)
Plasma

AngII

(pg/mL)
Plasma renin
(pg/mL/30 min)
Heart
rate (bpm)
Pulse pressure
(mmHg)
Mean

#

#

267.4±143.1

0.97 ± 0.31

arterial

pressure
(mmHg)
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#

24 hours

118.1 ± 0.6

115.0 ± 1.5

116.7 ± 3.9

115.0 ± 1.9

Light cycle

130.1 ± 1.0

123.6 ± 1.1*

130.0 ± 3.9

127.3 ± 2.0

Dark cycle

141.2 ± 2.1

139.1 ± 0.9

145.3 ± 5.5

142.6 ± 2.7

24 hours

136.0 ± 1.3

132.0 ± 1.1

137.7 ± 4.7

135.0 ± 2.3

Light cycle

94.6 ± 0.6

90.0 ± 1.9

89.2 ± 3.0

88.8 ± 1.5

Dark cycle

102.2 ± 0.7

101.7 ± 1.9

99.6 ± 3.9

98.4 ± 2.0

24 hours

98.7 ± 0.2

96.4 ± 2.0

94.4 ± 3.4

93.6 ± 1.7

Light cycle

3.3 ± 0.5

4.3 ± 0.4

4.2 ± 0.5

3.7 ± 0.3

Dark cycle

7.9 ± 0.8

14.0 ± 0.9*

12.0 ± 2.6

11.5 ± 1.9

Systolic blood
pressure
(mmHg)

Diastolic blood
pressure
(mmHg)

Activity
(counts/min)

Data are mean + SEM (n = 4-8 mice/treatment/genotype)
*, P<0.05 compared to vehicle within genotype; #, P<0.05 compared Ace2+/+
within treatment group
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Table 2.2 Characteristics and radiotelemetry parameters of HF-fed Ace2+/y
and Ace2-/y male mice administered vehicle or E2.
Male mice

Ace2

+/y

Vehicle
Body weight (g)

E2

Vehicle

E2

48.8 ± 2.1

46.7 ± 1.5

45.2 ± 3.8

Fat mass (g)

19.4 ± 1.9 19.7 ± 1.2

17.9 ± 1.6

16.0 ± 2.5

Lean mass (g)

26.2 ± 0.7 25.5 ± 1.0

24.0 ± 0.7

24.8 ± 0.8

Heart weight (g)

49.0 ± 2.0

-/y

Ace2

0.19 ± 0.01

0.18 ± 0.01

0.17 ± 0.01

0.17 ± 0.01

5.75 ± 0.78

5.72 ±0.62

5.16 ± 0.61

5.19 ± 0.89

117.4 ± 13.6

121.0 ± 23.0

112.3 ± 8.5

128.2± 18.6

1.74 ± 0.51

1.45 ± 0.32

1.80 ± 0.40

1.25 ± 0.17

608 ± 6

611 ± 6

599 ± 6

612 ± 4

36.5 ± 2.0

37.8 ± 0.9

37.2 ± 2.0

37.7 ± 2.3

112.0 ± 0.5

113.3 ± 1.2

109.5 ± 1.5

109.8 ± 1.8

Serum
E2 (pg/mL)
Plasma
AngII (pg/mL)
Plasma renin
(pg/mL/30 min)
Heart
rate (bpm)
Pulse pressure
(mmHg)
Mean arterial
pressure
(mmHg)
Light cycle
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Dark cycle

128.4 ± 1.2

127.3 ± 0.8

125.2 ± 2.9

127.2 ± 2.5

24 hours

120.2 ± 0.8

120.3 ± 1.0

117.3 ± 2.1

118.5 ± 2.0

Light cycle

128.5 ± 1.1

130.6 ± 1.4

126.1 ± 2.0

126.7 ± 2.5

Dark cycle

147.4 ± 1.4

146.8 ± 1.1

145.5 ± 3.9

147.0 ± 3.6

24 hours

138.0 ± 1.2

138.7 ± 1.2

135.3 ± 2.9

136.8 ± 3.0

91.5 ± 1.2

91.9 ± 1.5

Systolic blood
pressure (mmHg)

Diastolic blood
pressure (mmHg)
Light cycle

94.5 ± 1.1 94.9 ± 1.0

Dark cycle

108.4 ± 1.9

106.8 ± 0.7

104.5 ± 2.0

106.3 ± 2.0

24 hours

101.5 ± 1.4

100.8 ± 0.8

98.0 ± 1.5

99.1 ± 1.7

Light cycle

2.0 ± 0.3

2.4 ± 0.4

1.9 ± 0.3

2.6 ± 0.6

Dark cycle

8.2 ± 0.8

8.6 ± 0.5

11.1 ± 2.3#

12.8 ± 2.7#

Activity
(counts/min)

Data are mean + SEM (n = 5-9 mice/treatment/genotype)
*, P<0.05 compared to vehicle within genotype; #, P<0.05 compared to Ace2+/y
within treatment group.
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Figure 2.1 Effects of estrogen (E2) administration at various doses in
ovariectomized (Ovx) female mice fed standard mouse diet. (A) Serum E2
concentrations in intact versus Ovx females administered vehicle or different
doses of E2 for 1 month. (B) Uterine weights of mice in each group. Data are
mean ± SEM from n = 5-10 mice/group. *, P<0.05 compared to intact female
mice.
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Figure 2.2 E2 administration significantly decreases body weight and fat
mass of Ovx HF-fed Ace2+/+ and Ace2-/- female mice. (A) Body weights and
(B) fat mass (% body weight) of HF-fed female Ace2+/+ or Ace2-/- female mice
administered vehicle or E2 (36 µg/ml). Data are mean ± SEM from n = 8-12
mice/group/genotype. *, P<0.05 compared to vehicle within genotype.
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Figure 2.3 E2 administration reduces plasma AngII concentrations and
stimulates adipose ACE2 mRNA abundance and activity in HF-fed Ovx
Ace2+/+, but not in Ace2-/- female mice. (A) Plasma AngII concentrations in
HF-fed female Ace2+/+ and Ace2-/- Ovx mice.

(B) Adipose ACE2 mRNA

abundance and (C) ACE2 activity in HF-fed female Ace2+/+ and Ace2-/- Ovx mice.
Data are mean ± SEM from n = 8-12 mice/treatment/genotype.

*, P<0.05

compared to vehicle within genotype. #, P<0.05 compared to Ace2+/+ within
treatment.
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Figure 2.4 Effects of E2 administration on kidney ACE2 mRNA and
enzymatic activity in HF-fed Ovx female mice of each genotype. (A) Kidney
ACE2 mRNA abundance in HF-fed Ovx female mice. (B) Kidney ACE2 activity in
HF-fed Ovx female mice.

Data are mean ± SEM from n = 5-10

mice/group/genotype. *, P<0.05 compared to vehicle within genotype.
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Figure 2.5 E2 administration lowers SBP of HF-fed Ace2+/+, but not Ace2-/Ovx female mice during the light, but not the dark cycle. (A) SBP during the
light or (B) dark cycle or (C) 24 hour average SBP in HF-fed female Ace2+/+ and
Ace2-/- Ovx female mice.

Data are mean ± SEM from n = 6-9

mice/group/genotype. *, P<0.05 compared to vehicle within genotype.
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Figure 2.6 E2 administration has no effect on the development of obesity,
tissue (adipose and kidney) ACE2 mRNA and enzymatic activity in HF-fed
male mice of each genotype. (A) Body weights, (B) fat mass (% body weight),
(C) adipose ACE2 mRNA abundance and (D) adipose ACE2 activity in HF-fed
male Ace2+/y or Ace2-/y male mice administered vehicle or E2 (36 µg/ml). (E)
Kidney ACE2 mRNA abundance and (F) activity in HF-fed male Ace2+/y or Ace2-/y
mice administered vehicle or E2 (36 µg/ml). Data are mean ± SEM from n = 6-9
mice/group/genotype. *, P<0.05 compared to vehicle within genotype. #, P<0.05
compared to Ace2+/y within treatment.
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Figure 2.7 E2 administration had no effect on SBP of HF-fed male mice of
either genotype. (A) SBP during the light, (B) dark cycle or (C) 24 hours in HFfed male Ace2+/y and Ace2-/y mice.

Data are mean ± SEM from n = 6-9

mice/group/genotype.
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Figure 2.8 ERα is abundantly expressed in adipose tissue of female mice,
and increases upon E2 administration. (A) mRNA abundance of ERα versus
ERβ in adipose tissue of HF-fed female Ace2+/+ Ovx mice. (B) ERα mRNA
abundance in adipose tissue from HF-fed Ovx female mice of each genotype
administered vehicle or E2.
mice/group/genotype.

Data are mean ± SEM from n = 5-10

*, P<0.05 compared to vehicle within genotype.

P<0.01 compared to ERα (by two-tailed t-test).
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Figure 2.9 E2 binds to the ACE2 promoter to stimulate ACE2 expression in
3T3-L1 adipocytes. (A) Incubation of 3T3-L1 adipocytes with E2 results in an
increase in ACE2 mRNA expression in 3T3L1 adipocytes that is abolished by an
ERα (MPPD, 100 nM) antagonist. (B) Incubation of 3T3-L1 adipocytes with E2
(12 hours) as assessed by ChIP results in the enrichment (two-fold) of ERα to a
putative estrogen response element (ERE) on the ACE2 promoter. (C) PCR
products (from B) illustrated by electrophoresis on a 2% agarose gel. Arrow
denotes predicted ACE2 promoter product size (201 bp). Data (A, B) are mean ±
SEM from n=3 independent experiments. *, P<0.05 compared to vehicle;
P<0.01 compared to E2 treatment.
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Section III. SPECIFIC AIM 2
3.1 Summary
We demonstrated that male mice with diet-induced obesity exhibit
hypertension that is associated with reduced plasma concentrations of
angiotensin-(1-7) (Ang-(1-7)). In contrast, obese female mice exhibit increased
plasma Ang-(1-7) and are protected from obesity-induced hypertension. Ang-(17) is a ligand for Mas receptors (MasR), where the peptide has been reported to
promote endothelial release of nitric oxide and reduce blood pressure.
Conversely, MasR deficient mice have increased blood pressure (baseline and in
some experimental models of hypertension) and also exhibit reduced cardiac
function. In this study, we hypothesized that MasR deficiency will abolish
protection of female high fat (HF)-fed mice from the development of obesityinduced hypertension and augment hypertension in obese male mice.
Male and female (8 weeks age, C57BL/6) wild type (MasR+/+) and whole body
MasR deficient mice (MasR-/-) were fed a HF (60% Kcal as fat) or LF (10% Kcal
as fat) diet for 16 weeks. Baseline blood pressure was quantified by tail cuff
plethysmography. MasR deficiency had no effect on blood pressure at baseline
(on chow diet) in either sex and had no effect on the development of obesity in
HF-fed male and female mice. At week 16 of diet challenge, blood pressure was
quantified by radiotelemetry. In females, SBP was not affected by either diet or
genotype. However, deficiency of MasR resulted in a significant elevation of DBP
in HF-fed obese female mice compared with LF controls and conferred obesityhypertension in female mice. In contrast, HF-fed male mice exhibit significant
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increased SBP compared with LF control regardless of genotype. However, SBP
was significantly lower in HF-fed MasR-/- mice compared to HF-fed controls. DBP
were only increased in MasR+/+ but not in MasR-/- obese male mice compared
with LF controls respectively. In addition, DBP in MasR-/- obese male mice are
significantly lower than those in MasR+/+ obese mice.
Chow-fed MasR-/- mice of both sexes exhibited significantly decreased
ejection fraction (EF) compared to MasR+/+ mice. Use of cardiac magnetic
resonance (CMR) imaging in male mice revealed that the reduction in left
ventricular (LV) EF in MasR-/- mice at baseline was associated with a reduced LV
end-diastolic thickness to radius ratio (H/R ratio), indicating an eccentric cardiac
hypertrophic phenotype. However, the differences in LVEF and H/R ratio were no
longer apparent after 1 month of HF feeding. Infusion of Ang-(1-7) to 1 month
HF-fed MasR+/+ male mice restored LVEF to baseline levels, but had no effect on
LV function in HF fed MasR-/- male mice. Both LF and HF diet resulted in
significantly reducted LVEF in MasR+/+ but not MasR-/- male or female mice, and
the baseline differences in LVEF between genotypes were no longer apparent
after 4 months of diet challenge.
Results from this study support the hypothesis that Ang-(1-7) effects at MasR
protect female mice from the development of obesity-hypertension. In addition,
MasR is a critical determinant of cardiac health in both male and female mice.
From the clinical perspective, results from this study suggest novel drugs that are
able to activate MasR may afford extra benefit in hypertensive patients with
cardiac complications.
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3.2 Introduction
The etiology of obesity-induced hypertension has not been fully elucidated.
Studies suggest an activated renin-angiotensin system (RAS) as one of the
major underlying mechanisms responsible for the development of obesityinduced hypertension in experimental models and humans [8]. Moreover, in
addition to the classic RAS, alterations in the counter-regulatory arm of the
system, including angiotensin converting enzyme 2 (ACE2) and the angiotensin(1-7) (Ang-(1-7))/mas receptor (MasR) axis, have been suggested to contribute
to obesity-induced hypertension. Our laboratory has focused on the role of RAS
components, including ACE2, in differential susceptibility to obesity-induced
hypertension between male and female mice [53, 122]. Indeed, recent studies
from our laboratory demonstrated that a suppressed ACE2/Ang-(1-7)/MasR axis
contributed to obesity-induced hypertension in male mice, whereas females
exhibited increased adipose ACE2 expression and elevated plasma Ang-(1-7)
concentrations, protecting them from obesity-induced hypertension [53].
Ang-(1-7), an endogenous ligand of the G-protein coupled MasR, exerts
several effects that counter-balance actions of angiotensin II (AngII), including
stimulation of nitric oxide (NO) release from endothelial cells via the PI3K/Akt
pathway [72, 73]. Mice deficient in MasR exhibit impaired in vitro and in vivo
heart function, endothelial dysfunction, and elevated blood pressure, indicating a
potentially important role of the Ang-(1-7)/MasR axis in the regulation of blood
pressure homeostasis and cardiac function. While MasR deficient mice fed a
standard diet exhibited elevated blood pressure, no studies have examined
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effects of MasR deficiency on the development of obesity-induced hypertension,
even though several studies have linked Ang-(1-7)/MasR effects to models of
type II diabetes [246-249].
In addition to hypertension, obesity is associated with both systolic and
diastolic dysfunction of the left ventricle (LV) [250]. In a study of 6,076 heart
failure patients, the prevalence of obesity in subjects with preserved LV ejection
fraction (LVEF) and subjects with reduced LVEF are 41.4% and 35.5%,
respectively [251]. While human studies frequently show impaired LV diastolic
function with obesity, the effect of obesity on LV systolic function is somewhat
controversial [252]. Moreover, despite the high prevalence of obesity and heart
diseases in American women, obesity associated cardiac dysfunction in women
remains poorly understood. Thus, it is important to define mechanisms for sex
differences in obesity associated cardiac dysfunction. Similar to humans, the
effect of obesity on cardiac function in animal models is inconsistent. Some
studies reported impaired cardiac function [253-255], while others reported
normal cardiac function in rodent models of obesity [256, 257]. Although obesity
associated cardiac dysfunction is multifactorial, an activated RAS has been
suggested to play a critical role in the pathogenesis of LV dysfunction associated
with obesity [175, 258].
Previous research in our laboratory demonstrated that blockade of MasR
eliminated protection of female mice from obesity-hypertension [53]. These
results suggest that Ang-(1-7) activation of MasR may protect females from
obesity-hypertension. Conversely, in male obese mice exhibiting obesity-
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hypertension, plasma Ang-(1-7) concentrations were markedly decreased,
suggesting that low activity of the Ang-(1-7)/MasR axis may increase
susceptibility to obesity-hypertension in males [53]. In this study, we
hypothesized that MasR deficiency will abolish protection of female mice from
obesity-induced hypertension and augment obesity-induced hypertension in male
mice.

Additionally, a major aim of this study was to define effects of MasR

deficiency on cardiac function in mice with diet-induced obesity.

101

3.3 Materials and Methods
3.3.1 Animal Handling
All studies using mice were approved by an Institutional Animal Review
Committee at the University of Kentucky and were conducted in accordance with
the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals. MasR heterozygous (MasR+/-) founders on a C57BL/6 (Taconic)
background were purchased from VelociGene KOMP (Davis, CA). Experimental
male and female mice with MasR deficiency (MasR-/-) and wild type littermate
controls (MasR+/+) were generated by breeding Mas+/- male to MasR+/- female
mice. At 8 to 10 weeks of age, male and female mice were randomly assigned to
either receive high fat diet (HF; 60% kcal as fat; D12492, Research diets, Inc,
New Brunswick, NJ) or low fat diet (LF; 10% kcal as fat; D12450B, Research
Diets, Inc, New Brunswick, NJ) ad libitum for 16 weeks. There were 4 groups of
mice in each sex with n=6-9 mice/group: MasR+/+, LF; MasR-/-, LF; MasR+/+, HF;
MasR-/-, HF;). Body weight was recorded at baseline and every week throughout
the studies. Echocardiography was performed on isoflurane-anesthetized male
and female mice by Vevo2100 at baseline, 1 and 4 months of diet challenge. At
study endpoint, body composition was quantified in conscious mice by echo-MRI.
In a separate study, 1-month HF-fed male MasR+/+ and MasR-/- mice (n=4-5 per
group) were infused via osmotic minipump (Alzet, model 2006) with Ang-(1-7)
(0.4 µg/kg/min, Bachem, Torrence, CA) [259] for 28 days, echocardiography was
performed at baseline, before and after Ang-(1-7) infusion. At study end point,
mice were anesthetized with ketamine-xylazine (100:10 mg/kg ip) for
exsanguination and tissue harvest.
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3.3.2 Quantification of Plasma Parameters
Plasma Ang-(1-7) concentrations were quantified by ELISA using a
commercial kit (Bachem, CA) which exhibits minimal cross-reactivity to AngII.
Plasma renin concentrations were quantified as described previously [95].
3.3.3 Quantification of Blood Pressure
Blood pressure was quantified by radiotelemetry at week 16 of HF feeding as
described previously [260].

Briefly, at week 15 of HF feeding, anesthetized

(isoflurane to effect) mice were implanted with left carotid artery catheters
followed by a one week recovery, and then blood pressure was recorded
(sampling every 5 minutes) for 5 consecutive days.
3.3.4 Echocardiography studies
Mice were anesthetized in a plexiglass chamber by using 2-4% isoflurane at
effect according to their size, and then transferred to a heated platform kept at
37°C with 1-2% isoflurane supply through nose cone. All hair on the chest region
was shaved and removed, and electrode cream was applied on the front and
hindlimbs before being secured with electrical tape to electrodes on the platform.
Respiration rate (RR) and heart rate (HR) were monitored and adjusted to a
certain range across all experimental mice by titrating isoflurane levels. An RR of
100 times/min and HR of 400 beats/min was targeted. Images of the crosssectional view of the left ventricle at the papillary muscle level were obtained in
M-mode using an M550 transducer under the cardiology package on the
Vevo2100. Images were analyzed using Vevo 2100 software, and LV trace
methodology was chosen for -calculation of LV ejection fraction (LVEF, %).
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3.3.5 Cardiovascular Magnetic Resonance (CMR)
To confirm the echocardiography data on LV function and to get more insight
structural changes of the LV, CMR imaging was performed on desflurane (% at
effect) anesthetized male mice (baseline and 1 moth of HF feeding) with a 7Tesla Bruker CliScan (Bruker Ettlingen, Germany). Desflurane was adjusted to
maintain RR of 100 times / min. Core temperature of the mouse was maintained
at 37°C with a heated water blanket. Image acquisition has been described
elsewhere [261]. Images on 9-11 cross section slices with 1 mm interval were
taken to cover the entire mouse heart. Images of end systolic and end diastolic
phases of the middle 7 cross section slices were used to calculate LVEF. LV wall
thickness and dimensions were measured at end diastole to calculate H/R ratio.
3.3.6 Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were performed
using SigmaStat (SPSS). For 2 factor analysis, a two-way ANOVA (genotype
and treatment as between group factors, time as a repeated measure when
applicable) was used to analyze end-point measurements followed by HolmSidac for post hoc analyses. Values of P < 0.05 were considered to be
statistically significant.
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3.4 Results
3.4.1 MasR deficiency has no effect on the development of HF dietinduced obesity in female or male mice.
Female and male MasR+/+ and MasR-/- mice exhibited significant increases in
body weight in response to the HF diet (Figure 3.1A and B, P<0.05). Moreover,
HF diet-induced weight gain was not significantly different between genotypes in
male (MasR+/+: 18.7± 1.2g; MasR-/-: 19.4± 2.0g) and female mice (MasR+/+: 26.7
± 1.3 g; MasR-/-: 28.2 ± 1.1g). HF feeding resulted in decreased lean mass and
increased fat mass (expressed as percentage body weight) in female (Figure 3.1
C, E) and male (Figure 3.1 D, F) mice, with no significant differences between
genotypes.
3.4.2 MasR deficiency increases DBP in HF-fed female mice but
eliminates obesity-induced elevations in DBP in HF-fed male mice.
In female MasR+/+ mice, systolic blood pressure (SBP, 24 hour average over
5 days) was not significantly different between LF and HF-fed mice (Figure 3.2A).
Moreover, there was no significant difference in SBP between female LF or HFfed MasR+/+ and MasR-/- mice. There was an overall significant effect of HF diet
to increase DBP and mean arterial pressure (MAP, Table 3.1, P<0.05) in both
MasR+/+ and MasR-/- female mice. However, pairwise statistical analysis indicated
that DBP and MAP were significantly increased in HF-fed compared to LF-fed
female MasR-/- mice (DBP: LF, 84.8 ± 1.4 mmHg, HF, 92.3 ± 1.3mmHg; P<0.05),

105

but not in female MasR+/+ mice (DBP: LF, 85.2 ± 0.5 mmHg, HF, 88.5 ± 2.4
mmHg; Figure 3.2C).
In MasR+/+ male mice, HF feeding resulted in significantly elevated SBP
(Figure 3.2B; P<0.05), DBP (Figure 3.2D; P<0.05) and MAP (Table 3.2, P<0.05)
compared to LF-fed controls. MasR-/- HF-fed mice exhibited a significant increase
in SBP compared to LF-fed MasR-/- mice (Figure 3.2B; P<0.05). However, SBP
was significantly lower in HF-fed MasR-/- mice compared to HF-fed controls
(Figure 3.2B; P<0.05). Moreover, MasR-/- mice did not exhibit a significant
increase in DBP when challenged with a HF diet (MasR-/-: LF, 88.5 ± 0.5 mmHg,
HF, 89.8 ± 0.7 mmHg). Moreover DBP of HF-fed MasR-/- mice was significantly
decreased compared to HF-fed MasR+/+ mice (Figure 3.2D, P<0.05).
Previous

studies

demonstrated

that

HF

feeding

regulated

plasma

concentrations of Ang-(1-7) in both male and female mice [53]. Therefore, we
quantified plasma Ang-(1-7) concentrations in LF and HF-fed female and male
MasR+/+ and MasR-/- mice. In females, HF feeding resulted in a significant
elevation of plasma Ang-(1-7) concentrations in MasR+/+ (LF, 0.30 ± 0.04ng/ml,
HF, 0.87 ± 0.10 ng/ml), but not in MasR-/- mice (LF: 0.53 ± 0.13 ng/ml, HF: 0.69 ±
0.23 ng/ml; Figure 3.3A, P<0.05). Moreover, plasma Ang-(1-7) concentrations in
female HF-fed MasR-/- mice were significantly decreased compared to HF-fed
MasR+/+ mice. In male mice, plasma Ang-(1-7) concentrations were not affected
by either diet or genotype (Figure 3.3B).
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3.4.3 MasR deficiency reduces LV function in both female and male mice
at baseline.
LV function is impaired in MasR-/- mice at baseline; however, reductions in LV
function in MasR deficient mice are no longer evident with chronic HF feeding.
We assessed LV function by echocardiography in female and male MasR+/+ and
MasR-/- mice fed standard murine diet. At baseline, MasR-/- mice exhibit reduced
EF compared to wild type littermates (Figure 3.4A, B, P<0.01). However, after 4
months of LF or HF feeding, there were no significant differences between
genotypes in either sex (Figure 3.4C and D).
3.4.4 Ang-(1-7) infusion restores LV function in HF-fed male MasR+/+, but
not in MasR-/- mice.
We initiated studies in 1 month HF-fed MasR+/+ and MasR-/- male mice and
used CMR imaging to quantify cardiac morphology and function. We chose male
mice for these studies as baseline differences in cardiac function between
MasR+/+ and MasR-/- mice were more pronounced in males. At baseline, MasR-/mice exhibited significantly reduced EF (MasR+/+, 59.3 ± 2.1 %, MasR-/-, 51.4 ±
2.5 %, P<0.05, Figure 3.5A) which was associated with a significantly decreased
H to R ratio (H/R, %, MasR+/+, 50.5 ± 2.3 %, MasR-/-, 44.2 ± 1.2 %, P<0.05,
Figure 3.5B) compared to MasR+/+ mice. These results suggest an eccentric
hypertrophy LV phenotype in MasR-/- mice. In response to 1 month of HF
feeding, MasR-/- mice exhibited a significant increase in H/R ratio. In contrast,
H/R ratio was not altered in MasR+/+ mice after 1 month of HF feeding.
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Since EF was decreased in MasR-/- male mice at baseline and after 1 month
of HF feeding, we quantified EF by echocardiography in MasR+/+ and MasR-/mice fed a HF diet for 1 month, followed by a 1 month infusion of Ang-(1-7). Our
goal was to determine if reductions in EF of 1 month HF-fed MasR+/+ mice
resulted from reduced plasma concentrations of Ang-(1-7) [53]. After one month
of HF feeding, EF was reduced (by 15%) compared to baseline in MasR+/+, but
not in MasR-/- mice (Figure 3.5C). In MasR+/+ mice, infusion of Ang-(1-7) for one
month significantly increased EF to levels that were not significantly different
from baseline (Figure 3.5C). As expected, Ang-(1-7) infusion had no effect on EF
in HF-fed MasR-/- mice.
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3.5 Discussion
MasR, the receptor for endogenous Ang-(1-7), has been reported to play an
important role in maintaining BP homeostasis in several experimental animal
models [176, 188, 262]. While MasR deficiency in mice fed standard murine diet
results in impaired heart function and endothelial dysfunction, its effects on BP
are inconsistent [176, 177, 188]. Our lab has previously demonstrated that obese
female mice exhibit increased plasma Ang-(1-7) concentrations, which may
protect female mice from obesity-induced hypertension through MasR activation,
since pharmacological inhibition of MasR with D-Ala-Ang-(1-7) conferred obesityhypertension in HF-fed female mice [53]. While this finding suggested a possible
role of MasR in diet-induced obesity-hypertension in female mice, no studies
have examined the effect of MasR deficiency on the development of obesityinduced hypertension in male or female mice. The results of this study
demonstrate that MasR is a critical determinant of cardiovascular health in male
and female mice fed standard murine diet, as well as in mice with diet-induced
obesity. The major findings of the present study are 1) MasR deficiency results in
increased DBP and promotes obesity-hypertension in obese female mice, 2) in
contrast, MasR deficiency eliminates obesity-induced elevations of DBP in male
mice, 3) MasR deficient mice of both genders have reduced EF at baseline;
reductions in LVEF in male MasR-/- mice were associated with reduced H/R
ratios, suggesting eccentric hypertrophy of the LV, 4) Ang-(1-7) infusion restores
1 month HF diet-induced reductions in EF in MasR+/+, but not in MasR-/- mice.
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Studies in our laboratory have demonstrated an important role of the counterregulatory arm of the RAS, the ACE2/Ang-(1-7)/MasR axis, in the development of
obesity-hypertension in animal models of obesity. Obese male mice exhibiting
reduced kidney activity of ACE2 and reduced plasma concentrations of Ang-(1-7)
compared to LF controls were susceptible to obesity-hypertension, whereas
obese female mice exhibiting increased adipose ACE2 activity and increased
plasma Ang-(1-7) concentrations compared to LF controls were resistant to
obesity-hypertension [53]. Interestingly, ovariectomy (OVX) reduced plasma Ang(1-7) concentrations and conferred obesity-hypertension in female mice.
Moreover, administration of 17-β-estradiol (E2) lowered both plasma AngII
concentrations and blood pressure in HF-fed OVX female Ace2+/+, but not Ace2-/mice [219]. These studies suggest a positive correlation of plasma AngII
concentrations and a negative correlation of plasma Ang-(1-7) concentrations
with blood pressure in obese male and female mice, which fit well with the dual
function of ACE2 to both reduce the levels of AngII and increase those of Ang-(17). However, the role of the Ang-(1-7)/MasR axis in the development of obesityhypertension has not been directly defined. Results from this study extend
previous findings related to ACE2 protection of female mice from obesityhypertension and demonstrate that Ang-(1-7), acting through the MasR, may
partially account for the beneficial effect of stimulated ACE2 to protect obese
females from obesity-hypertension, as deficiency of MasR resulted in elevated
DBP of obese female mice. In contrast to the hypertensive phenotype caused by
either ACE2 deficiency or OVX previously reported in females [53], MasR
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deficiency in HF-fed female mice did not result in changes in SBP. These results
suggest that effects of ACE2 deficiency or OVX to promote increases in SBP in
obese females are unrelated to the Ang-(1-7)/MasR axis. A likely mechanism for
effects of ACE2 deficiency or OVX to increase SBP in obese females is through
augmented effects of AngII effects at AT1R.
Surprisingly, MasR deficiency in obese male mice did not result in a further
increase in blood pressure. Rather, both SBP and DBP were reduced in obese
MasR-/- compared to MasR+/+ mice. Moreover, the obesity-induced elevation of
DBP seen in obese MasR+/+ mice was absent in obese MasR-/- mice. The lack of
effect of MasR deficiency to further increase BP in obese hypertensive male mice
might be attributed to the inability of HF diet to stimulate plasma Ang-(1-7)
concentrations as in HF-fed female MasR+/+ mice. Since plasma Ang-(1-7)
concentrations of HF-fed male mice did not increase compared to LF controls, as
they did in HF-fed female mice, the effect of MasR deficiency may not be
manifest when the ligand is diminished. While it is not clear why MasR-/- HF-fed
male mice exhibit reduced BP in the face of pronounced obesity, one possible
explanation is that low BP may be the consequence of compromised cardiac
function. As demonstrated previously and from results of the present study,
MasR deficient male mice fed standard murine diet exhibit impaired heart
function in vitro and in vivo [177]. Notably, previous results demonstrate that
reduced BP in MasR deficient C57BL/6 mice was associated with lower cardiac
output [177]. Results from this study agree with previously published findings in
male mice and extended these findings to female mice.
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Human studies have suggested that obesity promotes hemodynamic
alterations as well as changes in cardiac morphology, and predisposes obese
people to heart diseases, such as heart failure [263]. Obese subjects are
frequently reported to exhibit elevated LV filling pressure which results in LV
hypertrophy and subsequent LV diastolic dysfunction, or LV systolic dysfunction,
or both [263]. Despite data suggesting that the prevalence of heart failure in
women is comparable to that of males, little is understood about heart failure in
women, and there tends to be delayed diagnosis of heart failure in women
compared to men [264]. To date, studies investigating the effect of obesity on
cardiac function using experimental models have generated mixed results and
focus almost exclusively on males. Thus, a direct comparison of LV function
between males and females with diet induced obesity is worthwhile.
In this study we examined the longitudinal effect of HF diet-induced obesity
on LV function in both male and female MasR+/+ and MasR-/- mice. As has been
demonstrated previously in males [177], MasR-/- male mice exhibit reduced LVEF
at baseline. Moreover, our results extend these findings to females, where MasR/-

mice exhibit reduced EF. Use of CMR in male mice revealed that the reduction

in LVEF in MasR-/- mice was associated with a reduced end-diastolic H/R ratio at
baseline compared to wild type littermates. Since H/R is measure of concentric
versus eccentric cardiac hypertrophy, reduced H/R ratios in MasR-/- mice suggest
an eccentric cardiac hypertrophic phenotype. Interestingly, the H/R ratio was
increased with HF feeding only in MasR-/- mice and was comparable to that of
MasR+/+ mice at 1 month HF feeding. These results suggest a compensatory
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remodeling of LV may be taking place in MasR-/- mice in response to HF
challenge. As a consequence of this remodeling, MasR-/- mice maintained EF in
response to 1 month of HF feeding, whereas MasR+/+ mice exhibited reductions
in LVEF with HF feeding (despite an unaltered H/R ratio). However, these
findings do not necessarily suggest that MasR deficiency is beneficial for LV
function in male mice, because 1) MasR-/- mice clearly have lower LVEF at
baseline compared to wild type controls, 2) LV remodeling is an early sign for LV
dysfunction in heart failure; thus, accelerated LV remodeling early in response to
HF-feeding in MasR-/- mice may become detrimental over time. However, as
there were no significant differences in LVEF between 4 month LF and HF mice
of either genotype, it is unclear how changes in LVEF and remodeling at 1 month
of HF feeding relate to long-term consequences of obesity. Obesity is associated
with enhanced oxidative stress, intracellular Ca2+ defects and reduced
mitochondrial density in cardiomyocytes which can lead to cardiac contractile
dysfunction [253]. Since HF-fed MasR+/+ mice showed no obvious structural
changes, the reduction in LVEF may be associated with mechanisms that impair
myocardial contractility.
We previously demonstrated that HF-fed obese male mice exhibit an increase
in the AngII/Ang-(1-7) balance [53]. Since results from other laboratories have
shown that Ang-(1-7), acting through the MasR, has been shown to counterregulate AngII/AT1R signaling in heart [166, 167, 169], we explored the effects of
Ang-(1-7) to restore LV function in HF-fed male mice. We choose a dose of Ang(1-7) which has been reported to significantly increase plasma concentrations of
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Ang-(1-7) in mice [259]. Infusion of Ang-(1-7) to 1 month HF-fed MasR+/+ male
mice restored LVEF to baseline levels, but had no effect on LV function in HF fed
MasR-/- male mice. These results indicate that reductions in LVEF in HF-fed male
MasR+/+ mice may be associated with imbalanced AngII/Ang-(1-7) signaling
which can be corrected by Ang-(1-7) administration.
Our results in 4 month HF-fed male and female wild type and MasR deficient
mice were surprising. First, baseline reductions in LVEF in MasR deficient mice
compared to wild type controls were no longer apparent after 4 months of HF
feeding. Moreover, there were no differences in LVEF between LF and HF-fed
mice of either genotype after 4 months of diet feeding. We offer several
possibilities to explain these findings. First, it is possible that aging influenced
LVEF in both LF and HF-fed animals. However, our results suggest that it is wild
type, and not MasR deficient mice that largely exhibited changes in LVEF over
time (bringing the two groups closer in LVEF at 4 months). Moreover, reductions
in LVEF in MasR+/+ male mice were evident at 1 month of HF feeding using two
different imaging modalities to assess cardiac function. Taken together, these
results suggest that aging is most likely not the primary contributor to the lack of
difference in LVEF between wild type and MasR deficient mice at 4 months of
diet feeding. A second possibility is an effect of anesthesia (either choice of
anesthetic or repeated anesthesia) to regulate cardiac function. Isoflurane (used
for echocardiography) has been reported to reduce cardiac function, which may
be more evident in small size LF-fed mice. However, CMR was performed at
baseline and in 1 month HF-fed mice of each genotype anesthetized with
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desflurane, an anesthetic that has not been reported to affect cardiac function.
Since results from CMR demonstrate reductions in LVEF in MasR deficient mice
at baseline and in wild type mice after 1 month of HF feeding, it is unlikely that
anesthesia is a primary contributor to data obtained at 4 months of HF feeding.
We suggest that it is possible that both the LF and HF diet have detrimental
effects on LV function through different mechanisms. Specifically, while the LF
diet used in this study is an appropriate control for HF feeding in regard to the
development of obesity and obesity-hypertension, it may not be an optimal
control diet for studies focused on cardiac function. The absence or the
overabundance of one fuel (fats or carbohydrates) may result in cardiac
metabolic toxicity and contractile dysfunction [265]. Indeed, acute depletion of
free fatty acid in heart failure patients resulted in depressed cardiac work and
efficiency [266]. Moreover, high carbohydrate intakes as well as carbohydrates
from refined starches or added sugars have been positively associated with
increased risk of heart diseases [267]. The low fat content (10% kcal from lard
and soybean oil) and extremely high carbohydrate content (70% kcal from
sucrose and corn starch) of the LF diet used in this study may have influenced
LVEF over time. Future studies should investigate different control diets for
obesity-related studies to address this question.
Taken together, results from this study support the hypothesis that Ang-(1-7)
effects at MasR protect female mice from the development of obesityhypertension. In addition, MasR is a critical determinant of cardiac health in both
male and female mice. From the clinical perspective, results from this study
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suggest novel drugs that are able to activate MasR may afford extra benefit in
hypertensive patients with cardiac complications.
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Table 3.1: Characteristics and radiotelemetry parameters of female MasR+/+
and MasR-/- mice fed a LF or HF diet.
Male mice

MasR+/+

MasR-/-

LF

HF

LF

HF

Body weight (g)

23.8 ± 0.8

47.9 ± 1.8*

23.8 ± 0.6

48.0 ± 1.4*

Fat mass (g)

3.3 ± 0.2

21.0 ± 1.8*

3.4 ± 0.2

23.6 ± 1.4*

Lean mass (g)

16.5 ± 0.2

18.3 ± 0.6*

16.4 ± 0.4

19.9 ± 0.6*,#

0.125±0.005

0.138±0.004

0.125±0.004

0.149±0.006*

0.30 ± 0.04

0.87 ± 0.10*

0.53 ± 0.13

0.46 ± 0.06#

5.36 ± 0.78

5.57 ± 0.80

5.33 ± 0.63

5.56± 0.70

611 ± 6

626 ± 8

595 ± 20

620 ± 5

14.1 ± 2.7

5.5 ± 0.5*

14.5 ± 4.5

6.0 ± 0.6*

35.1 ± 1.0

37.0 ± 1.5

36.2 ± 2.2

33.1 ± 1.0

Light cycle

99.4 ± 1.1

102.8 ± 2.0

97.6 ± 0.6

105.5 ± 0.7*

Dark cycle

109.2 ± 0.7

111.4 ± 2.0

108.4 ± 0.8

114.4 ± 1.0*

24 hours

104.3 ± 0.7

107.9 ± 2.0

103.0 ± 0.7

109.5 ± 1.0*

116.8 ± 0.5

119.4 ± 1.9

117.4 ± 0.5

121.0 ± 0.6

Heart weight
(g)
Plasma
Ang-(1-7)
(ng/mL)
Plasma renin
(pg/mL/30 min)
Heart rate
(bpm)
Activity
(counts/min)
Pulse pressure
(mmHg)
Mean arterial
pressure
(mmHg)

Systolic blood
pressure
(mmHg)
Light cycle
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Dark cycle

127.3 ± 0.6

128.5 ± 1.7

128.1 ± 0.4

131.1 ± 0.6

24 hours

122.1 ± 0.4

124.4 ± 1.8

122.8 ± 0.4

125.5 ± 0.7

Light cycle

80.5 ± 0.8

84.8 ± 2.5

80.2 ± 1.3

88.9 ± 1.0*

Dark cycle

89.9 ± 0.4

91.4 ± 2.3

89.3 ± 1.5

96.6 ± 1.3*,#

88.5.6 ± 2.4

84.8 ± 1.4

92.3 ± 1.3*

Diastolic blood
pressure
(mmHg)

24 hours
Data

are

85.2 ± 0.5
mean

±

SEM

(n

=

5-9

mice/treatment/genotype)

*, P<0.05 compared to LF within genotype; #, P<0.05 compared to MasR+/+ within
diet group.
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Table 3.2: Characteristics and radiotelemetry parameters of male MasR+/+
and MasR-/- mice fed a LF or HF diet.
Male mice

MasR+/+
LF

MasR-/HF

LF

HF

Body weight (g) 30.5 ± 1.3

41.7 ± 1.4*

31.3 ± 1.8

42.4 ± 2.1*

Fat mass (g)

6.9 ± 0.9

16.7 ± 0.7*

7.1 ± 1.4

16.5 ± 0.5*

Lean mass (g)

19.2 ± 0.4

22.0 ± 0.6*

18.4 ± 0.4

22.9 ± 0.3*

0.173±0.010*

0.136±0.005

0.166±0.005*

0.44 ± 0.06

0.44 ± 0.09

0.54 ± 0.06

5.38 ± 0.56

7.01 ± 0.60

6.53 ± 1.04

5.95± 0.80

571 ± 13

585 ± 8

550 ± 7

582 ± 10*

5.3 ± 1.2

4.2 ± 0.6

4.4 ± 0.7

4.0 ± 0.5

32.0 ± 2.1

36.3 ± 1.9

32.1 ± 1.3

38.6 ± 1.2*

Light cycle

100.8 ± 2.7

110.0 ± 1.3*

99.3 ± 0.4

105.9 ± 0.8*,#

Dark cycle

110.9 ± 1.6

118.4 ± 1.2*

110.5 ± 0.6

112.9 ± 0.8#

24 hours

105.8 ± 2.1

114.3 ± 1.2*

104.9 ± 0.3

109.4 ± 0.7*,#

115.7 ± 2.6

127.0 ± 1.0*

114.8 ± 0.5

124.2 ± 1.1*

Heart
weight
0.144±0.006
(g)
Plasma
Ang-(1-7)
0.51 ± 0.09
(ng/mL)
Plasma renin
(pg/mL/30 min)
Heart rate
(bpm)
Activity
(counts/min)
Pulse pressure
(mmHg)
Mean arterial
pressure
(mmHg)

Systolic blood
pressure
(mmHg)
Light cycle
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Dark cycle

127.5 ± 1.8

137.0 ± 0.7*

126.6 ± 1.3

132.7 ± 1.2*,#

24 hours

121.6 ± 2.1

132.0 ± 0.8*

120.7 ± 0.8

128.5 ± 1.1*,#

Light cycle

85.3 ± 3.3

92.1 ± 2.0*

83.4 ± 0.5

87.0 ± 0.8

Dark cycle

93.8 ± 2.4

99.1 ± 2.2

93.6 ± 0.7

92.5 ± 0.7

24 hours

89.5 ± 2.8

95.6 ± 2.1*

88.5 ± 0.5

89.8 ± 0.7#

Diastolic blood
pressure
(mmHg)

Data

are

mean

±

SEM

(n

=

5-9

mice/treatment/genotype)

*, P<0.05 compared to LF within genotype; #, P<0.05 compared to MasR+/+ within
diet group.
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Figure 3.1 MasR deficiency has no effect on the development of dietinduced obesity in male and female mice. A, B: Body weight in female (A) and
male (B) MasR+/+ and MasR-/- mice fed a low fat (LF) or high fat (HF) diet. C, D:
Lean mass (% body weight) at the end of 16 weeks in female (C) and male (D)
MasR+/+ and MasR-/- mice fed a LF or HF diet. E, F: Fat mass (% body weight) at
the end of 16 weeks in female (C) and male (D) MasR+/+ and MasR-/- mice fed a
LF or HF diet. Data are mean ± SEM from 8-10 mice/genotype/diet. * P<0.05 vs.
LF within genotype.
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Figure 3.2 MasR deficiency increases diastolic blood pressure (DBP) in
obese female mice, but eliminates obesity induced increase in DBP in
obese male mice. A, B: Systolic blood pressure (SBP, 24-hour average) in
female (A) and male (B) MasR+/+ and MasR-/- mice fed a LF or HF diet for 4
months. C, D: DBP (24-hour average) in female (C) and male (D) MasR+/+ and
MasR-/- mice fed a LF or HF diet. Data are mean ± SEM from 6-10
mice/genotype/diet. * P<0.05 vs. LF within genotype.
MasR+/+ within diet.
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#

P<0.05 compared with
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Figure 3.3 Plasma concentrations of Ang-(1-7) in female and male MasR+/+
and MasR-/- mice fed a LF or HF diet for 4 months. A, B: Plasma Ang-(1-7) in
female (A) and male (B) MasR+/+ and MasR-/- mice fed a LF or HF diet. * P<0.05
vs. LF within genotype. # P<0.05 compared with MasR+/+ within diet.
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Figure 3.4 Assessment of left ventricular (LV) function in female and male
MasR+/+ and MasR-/- mice at baseline and 4-months HF or LF feeding. A, B:
Ejection fraction (%, EF) of chow-fed female (A) and male (B) MasR+/+ and
MasR-/- mice at baseline. C, D: EF of 4-month LF or HF fed female (C) and male
(D) MasR+/+ and MasR-/- mice. Data are mean

± SEM from 8-10

mice/genotype/diet. ** P<0.01 compared with MasR+/+ mice.
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Figure 3.5 Ang-(1-7) administration restores LV function in HF fed male
MasR+/+ mice but has no effect in HF fed MasR-/- mice. CMR were performed
on male MasR+/+ and MasR-/- mice at baseline (on chow diet) and one-month HF
feeding. A: EF in male MasR+/+ and MasR-/- mice before and after HF feeding. B:
H/R ratio in male MasR+/+ and MasR-/- mice before and after HF feeding. Ang-(17) was administered to male mice via subcutaneous osmotic mini pump at one
month

of

HF

feeding

for

28

days;

LV

function

was

assessed

by

echocardiography. C: EF (%) in HF fed MasR+/+ and MasR-/- mice before and
after Ang-(1-7) administration. Data are mean ± SEM from 5 mice/genotype. *
P<0.05 compared with MasR-/- mice within time point.
within genotype.
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#

P<0.05 vs. 0 time point

Section IV. GENERAL DISCUSSION
4.1 Summary
The aim of the studies described in this dissertation was to understand the
role of the counter-regulatory arm of the RAS, ACE2/Ang-(1-7)/MasR axis in the
development of obesity-hypertension in male versus female mice. We studied the
role of two critical proteins in this axis, ACE2 and MasR, in the development of
HF diet-induced obesity-hypertension in male and female mice. Previous findings
from our lab suggest that differences in the tissue-specific regulation of ACE2
contribute to the sexual dimorphism of diet-induced obesity-hypertension in mice.
Specifically, female mice exhibited increased adipose ACE2 activity and
increased plasma concentrations of Ang-(1-7), and were resistant to diet-induced
obesity-hypertension. However, the protective mechanisms in females can be
overcome by either genetic deletion of ACE2 or by taking away female sex
hormones via ovariectomy (Ovx). While these findings provide some insights on
sexual dimorphism of obesity-hypertension, they raise the question of whether or
not the well described increase in hypertension prevalence of postmenopausal
women (who are commonly obese) was due to loss of estrogen-mediated
regulation of adipose ACE2.
The studies in Aim 1 of this dissertation were designed to examine the effect
of the female sex hormone, 17β-estradiol (E2), on the development of obesityhypertension in both male and Ovx female mice with or without deficiency of
ACE2. In response to HF-feeding, Ovx female mice exhibited a marked increase
in body weight, comparable to that of HF fed male mice, which was not observed
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in HF-fed females with intact ovaries. Also, the fat mass to body weight ratio at
study endpoint in HF-fed Ovx female mice was larger than that of HF-fed male
mice. Additionally, Ovx converted obese female mice to a hypertensive
phenotype, similar to that of obese male mice. Chronic E2 administration to HFfed Ovx female wild-type mice reduced SBP during the light cycle (the resting
phase for mice) and blunted the development of obesity-hypertension. E2mediated reductions in SBP were associated with increased ACE2 mRNA
abundance and increased ACE2 activity in adipose tissue, as well as a reduction
in plasma Ang II concentrations. Notably, these changes were not evident in
ACE2 deficient Ovx females with E2 administration, suggesting that E2-mediated
reduction in SBP is ACE2- dependent. While E2 administration reduced SBP in
wild-type HF-fed Ovx female mice, it also resulted in less weight gain, which
could have contributed to the effect of E2 to protect against obesity-hypertension.
However, a similar reduction in body weight in response to E2 was also evident
in hypertensive ACE2 deficient mice. Thus it is unlikely that an E2-mediated
reduction in weight gain served as the primary mechanism contributing to E2
mediated reductions in SBP of HF-fed Ovx female mice.
To understand the interaction between E2 and ACE2 at the molecular level,
we performed in vitro studies using mouse 3T3-L1 cells to verify evidence of E2
regulation of ACE2 in adipocytes. E2 mediated stimulation of ACE2 in
differentiated 3T3-L1 adipocytes was blunted by co-incubation with an ERα
antagonist. This is consistent with the observations in vivo that ERα, instead of
ERβ, is the dominant ER isotype expressed in adipose tissue, and that the
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expression of ERα was increased with E2 administration in wild-type HF-fed Ovx
female mice. Since previous studies have suggested the presence of a putative
estrogen response element (ERE) in the promoter region of the ACE2 gene
[232], we explored whether E2 regulates ACE2 gene expression through EREs in
the ACE2 promotor using 3T3-L1 adipocytes. A ChIP assay was performed in
fully differentiated 3T3-L1 adipocytes treated with E2 using an ERα antibody and
DNA fragments were amplified with primers designed around several putative
EREs in the ACE2 promoter. Results from this experiment revealed the
enrichment of ERα protein complex at one specific putative ERE on the ACE2
promotor. Collectively, these results demonstrate direct effects of E2 to promote
ACE2 expression in adipocytes through ERα-mediated interactions with ERE on
the ACE2 promoter.
Interestingly, the same E2 dose that resulted in reduced SBP of HF-fed Ovx
females showed no effect to protect against obesity-hypertension in HF-fed male
mice. In contrast to Ovx female mice, in which E2 administration significantly
increased serum E2 concentrations (table), chronic E2 administration in obese
male mice failed to increase serum concentrations of E2.

However, E2-

administered male mice exhibited reduced sex organ weight compared to
vehicle-treated mice, suggesting the successful delivery of E2 in male mice.
These results suggest that male mice may respond differently than female mice
to exogenous E2 with respect to both metabolism and cellular response.
Estrogen sulfotransferase family 1E member 1 (SULT1E1) is known to catalyze
the sulfoconjugation and deactivation of estrogens, thus is an important
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determinant of a cell’s response to estrogen because sulfonated estrogens can
no longer bind to ERs [268]. Moreover expression level of SULT1E1 is inversely
correlated with E2 malignancy [269]. We quantified SULT1E1 mRNA in liver from
male and Ovx female mice treated with E2 or vehicle. E2-administered male
mice exhibited mild but insignificant (P=0.066) elevation in liver SULT1E1 mRNA
abundance compared with vehicle controls. Whereas E2 administration had no
effect on liver SULT1E1 expression in Ovx female mice despite its overall
expression is significantly higher than that in male mice (data not shown).
Studies have been suggested the existence of sex dimorphism in tissue
expression of ERs [270, 271] including adipose tissue [272]. In human adipose,
ERα has been suggested to be the predominant isoform, but its expression is
reported to be identical between the genders. However, ERβ mRNA levels were
reported to be higher in women compare with men in both subcutaneous and
intraabdominal adipose depot [272]. Results from present study largely agreed
with those findings. We’ve demonstrated that ERα was the predominant ER
isoform in mouse adipose tissue, and the expression levels were not significant
different between genders. However, it is possible that the expression of ERβ is
different which influence ERα / ERβ balance and E2 response in male versus
female mice.
While studies in Aim 1 suggested that E2 protects against obesityhypertension in females through activation of ACE2 in adipocytes, the relative
contribution of ACE2 to repress the AngII/AT1R arm versus to stimulate the Ang(1-7)/MasR pathway remained unknown. Thus, in Aim 2 we examined the role of
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MasR deficiency in the development of obesity-hypertension in male versus
female mice. Specifically, we hypothesized that MasR deficiency will abolish
protection of HF-fed female mice from the development of obesity-hypertension
and augment obesity-hypertension in male mice. Several studies suggest an
important role of MasR in the regulation of cardiac function, which is also a
determinant of blood pressure. Thus, longitudinal assessments of LV function
were performed in MasR deficient and wild type mice of each gender with
obesity.
Female wild-type mice fed a HF diet did not develop obesity-hypertension.
However, MasR deficiency resulted in increased DBP of obese female mice
compared to lean controls and abolished the protection of female mice from
obesity-hypertension. Consistent with effects of MasR deficiency to increase
DBP, obese female mice exhibited robust elevations in plasma Ang-(1-7)
concentrations, whereas this obesity-related elevation in plasma Ang-(1-7)
concentrations was totally ablated in MasR-/- obese females. These results
demonstrate that Ang-(1-7) protects female mice from obesity-hypertension
through MasR activation.
In contrast to females, male wild-type mice fed a HF diet developed obesityhypertension. However, MasR deficiency in obese male mice did not result in a
further increase in blood pressure. Instead, both SBP and DBP were reduced in
obese MasR-/- mice compared to MasR+/+ mice. Previous studies in our
laboratory reported marked reductions in plasma Ang-(1-7) concentrations in
obese male mice compared with lean controls. However, in the present study,
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reductions in plasma Ang-(1-7) concentrations in obese male mice were not
statistically significant. This may be due to the less robust body weight
differences between LF and HF-fed male mice compared to previous studies.
It has been reported that male MasR deficient mice fed standard murine diet
exhibit impaired cardiac function [176, 177]. Results from the present study agree
with previous findings and extended these observations to female mice. Here we
showed that both male and female MasR-/- mice fed standard murine diet
exhibited reduced LVEF compared with wild type littermates. Interestingly, upon
chronic LF or HF feeding, both male and female MasR+/+, but not MasR-/- mice
exhibited significant reductions in LVEF compared to baseline values.

As a

result, there were no statistical differences in LVEF between MasR+/+ and MasR-/mice of either gender at 4 months of LF or HF-feeding. Although it is not clear
why chronic LF feeding resulted in similar reductions in LVEF to those seen in
HF-fed mice, this finding obscured determination of effects of diet-induced
obesity on LV function in male or female mice. To gain more insight in effects of
MasR deficiency on LVEF at baseline and the possible effect of short-term HF
feeing on LV function, CMR were performed on a subset of male mice at
baseline and one month of HF feeding. Along with reductions in LVEF, male
MasR-/- mice exhibited significantly lower H/R ratio at baseline, suggesting the LV
of MasR-/- mice exhibited an eccentric hypertrophic phenotype compared to wild
type littermates. Interestingly, in response to HF feeding, MasR-/- mice exhibited
an increase in H/R ratio probably as a consequence of compensatory LV
remodeling.

However, these mice maintained their low level of LVEF.
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In

contrast, HF-fed MasR+/+ mice showed significant reductions in LVEF but no
change in H/R ratio. These data suggested that distinct mechanisms were
involved for functional or structural changes in MasR+/+ versus MasR-/- mice
despite the fact that neither the LVEF nor H/R ratio was significant different
between genotypes at one month of HF feeding.
We previously demonstrated that HF-fed obese male mice exhibit an
increase in the AngII/Ang-(1-7) balance [53]. Moreover, Ang-(1-7), acting through
the MasR, has been shown to be able to counter-regulate deleterious effects
caused by AngII/AT1R signaling in the heart [166]. Therefore, we explored the
effects of Ang-(1-7) to restore LV function in HF-fed male mice of either
genotype. Administration of Ang-(1-7) to HF-fed MasR+/+ male mice restored
LVEF to baseline, but had no effect on LV function in HF-fed MasR-/- male mice.
These results indicate that reductions in LVEF in HF-fed male MasR+/+ mice may
be associated with imbalanced AngII/Ang-(1-7) signaling which could be
corrected by administration of Ang-(1-7).
4.2 Insights from estrogen regulation of ACE2
Obesity promotes hypertension, and an increase in adiposity is responsible
for recent rises in the prevalence of hypertension in both men and women [7].
Results from the present study suggest that estrogen stimulates adipose ACE2
to protect females against obesity-hypertension. These data may seem
contradictory in that adipose may be both a culprit and a benefit in the regulation
of blood pressure through an estrogen/ACE2-dependent mechanism. It is clear
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that obesity, or marked increases in adiposity, exert a negative impact on blood
pressure [8]. However, in females there may be one advantage to an expanded
adipose tissue mass with respect to blood pressure regulation, namely through
estrogen-mediated stimulation of ACE2 in adipose tissue.
Several studies have demonstrated increased conversion rates of Δ4androstenedione to estrone in both obese women and men [273, 274]. Moreover,
the increased conversion is largely attributed to an increased mass of adipose
tissue for there is a linear correlation between these two [275, 276]. Increased
estrogen produced as a result of adipose tissue expansion may function in a
paracrine fashion. Specifically, increased overall local estrogen concentrations
could stimulate adipose ACE2, contributing to protection of females from obesityhypertension. However, this protective mechanism to lower blood pressure may
become overwhelmed with worsening obesity or may disappear when females
reach menopause. Whether or not this increased estrogen production by adipose
tissue results in elevated blood estrogen concentrations in obese women is
debatable [275]. One study in postmenopausal women reported increased
estrogen with obesity [277], another reported a correlation between estrogen
levels and the degree of obesity [278] and others found no significant elevation of
blood estrogen levels in obese premenopausal or postmenopausal women [279,
280].
It has been suggested that obese males have elevated blood estrogen [281],
most likely as a result of increased adipose aromatase activity. However, due to
the lack of a designated organ for estrogen secretion, adipose-derived estrogen
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may not be enough to afford protection in obese males. Indeed, results from
these studies suggest that even with exogenous estrogen administration, the
expected protective mechanism may still be absent in obese males. Although in
our studies, the lack of effect of estrogen to reduce obesity-hypertension in males
could be explained by unchanged serum estrogen concentrations, the expression
of estrogen receptors in males may be a contributing factor. We compared the
levels of ERα mRNA abundance in adipose tissue among obese males, obese
females, and obese OVX females. Results suggested that the lowest ERα mRNA
abundance in adipose tissue was found in obese males and the highest in obese
OVX females, although the differences among the three didn’t reach statistical
significance.
While studies in this dissertation suggest that estrogen may afford protection
from obesity hypertension in postmenopausal women, many issues remain to be
clarified with regard to use of estrogen replacement therapy to treat hypertension
in post-menopausal women. There are two worthwhile questions to ask. Is it
safe? Is it effective? The effectiveness of hormone replace therapy (HRT) on
cardiovascular diseases has been investigated in several controlled clinical trials,
which generated mixed results, but overall the outcomes were far less effective
than expected. The most well-known controlled trial, the Women’s Health
Initiative (WHI), by the National Heart Lung and Blood Institute, investigated the
effect of HRT on overall CV events, cancer, and osteoporosis in 16,608 women,
ages 50 to 79. Participants were assigned to either take HRT (conjugated equine
estrogen, 0.625 mg/day + medroxyprogesterone acetate 2.5 mg/day, one tablet)
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or placebo and followed for 5.2 years, at which point the study was ended
prematurely. Although the all-cause mortality was balanced between groups,
women taking HRT compared with placebo showed more CHD events, strokes
and invasive breast cancers over one year of intervention, suggesting that HRT
is probably more harmful than beneficial on overall cardiovascular health in postmenopausal women.
While the WHI study provides valuable data on life-threatening diseases in
postmenopausal women, it may exert a negative influence on practicing
clinicians, patients, or even researchers who are not aware of the limitations of
the study, or over-interpret its conclusions. One of the most discussed points
across all HRT related trials is the drug regimen, which in the case of the WHI,
uses the combination of estrogen and progesterone. Actually, estrogen alone
was the dominant hormone used to prevent heart diseases in early studies and
was suggested to lower the risk of CVD [282]. Progestin was added with the
hope of reducing the risk of endometrial cancer associated with the use of
estrogen [282]. While accumulated evidence suggests that the combined
regimen may act very differently than estrogen alone, it also fails to consistently
prove that the combined regimen has less tumorigenic properties. In addition,
recent evidence from secondary prevention trials demonstrated increased risk of
CHD with combined estrogen/progestin therapy. Collectively, these studies
indicate that there are some negative progestin-dependent effects that may
outweigh beneficial effects of estrogen to reduce CVD. Moreover, the Data and
Safety Monitoring Board (DSMB) which recommended stopping the combined
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intervention portion of the WHI trial didn’t recommend stopping the portion of the
trial associated with use of estrogen alone. Thus, it is unknown if estrogen alone
may be safe and effective.
The timing associated with the initiation of HRT also may be important. The
prevalence and severity of CVD tends to increase with age, so it may be more
effective to prevent the onset of CVD than to try to reverse established CVD.
Many studies suggest that there may be changes in the level of ER expression at
effector sites in established CVD compared with healthy subjects [283, 284]. For
instance, the abundance of both ER subtypes (ERα and ERβ) in the aorta of
human decreases with the progression of atherosclerosis [285]. Interestingly,
ERβ has been suggested to exhibit inhibition on ERα-dependent regulation of
gene expression and vascular function, including facilitating NO-dependent
vascular relaxation [286]. Thus, both altered availability and disruption in the
balance between ERα and ERβ signaling may account for loss of estrogen
responsiveness in post-menopausal females. As support for this, results from the
present study demonstrated that the mRNA abundance of ERα in adipose tissue
was significantly higher in female OVX mice administered with estrogen
compared with vehicle treated mice. In addition, since the estrogen
administration was initiated immediately following ovariectomy and throughout
the duration of HF-feeding, effects of estrogen in female mice in this study may
represent early prevention rather than reversal of obesity-hypertension.
4.3 Insight from MasR deficiency: Role in obesity-hypertension and regulation
of cardiac function
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Previous studies in our laboratory have demonstrated that obese female
mice exhibit stimulated adipose ACE2 activity and elevated plasma Ang-(1-7)
concentrations and were resistant to obesity-hypertension. Conversely, ACE2
deficiency resulted in reduced plasma Ang-(1-7) concentrations and conferred
obesity-hypertension in female mice [53]. We hypothesized that MasR deficiency
would increase blood pressure in obese female mice as did ACE2 deficiency,
since MasR is the receptor for endogenous Ang-(1-7) and mediates the biological
actions of the heptapeptide. Results from the present study demonstrated that
MasR deficiency indeed increased blood pressure in obese female mice, but it
did so only in the form of increased DBP. An increase in DBP with MasR
deficiency is consistent with published findings that Ang-(1-7), via MasR,
stimulates endothelium release of NO to dilate arteries [72, 287]. In addition,
vessels from MasR deficient animals exhibit impaired relaxation and increased
resistance [71, 188], which are critical determinants for blood pressure during
diastole. However, there are some differences compared to findings from studies
using ACE2 deficient mice, where increases in SBP have consistently been
observed. Our results from MasR deficient mice exhibiting increased DBP
indicate that effects of ACE2 on BP regulation may consist of two parts. The Ang(1-7)/MasR arm may contribute to regulation of the diastolic portion of BP, and
the AngII/AT1R arm may contribute to regulation of the systolic portion of BP. In
support of this theory, results from Aim 1 demonstrated that a reduction in SBP in
E2-administered Ovx female mice was associated with elevated adipose ACE2
activity and mRNA abundance and reduced plasma AngII concentrations.
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Numerous studies have suggested that females have higher plasma Ang-(17) concentrations compared to males in both humans and in animal models of
hypertension. In healthy humans, women have been shown to exhibit higher
circulating concentrations of Ang-(1-7) compared to men, whereas levels of AngII
were not significantly different between genders [288]. In addition, a positive
correlation between Ang-(1-7) concentrations and DBP was observed in women
but not in men [288]. Collectively, these findings suggest Ang-(1-7) may be more
active in the regulation of BP in females than males. In murine models of dietinduced hypertension, obese male mice exhibited diminished plasma Ang-(1-7)
concentrations [53], suggesting that the Ang-(1-7)/MasR axis in obese male mice
is in a repressed or even inactive status. As support for this, in this study MasR
deficiency failed to further increase BP in obese hypertensive male mice.
Evidence indicates the Ang-(1-7)/MasR axis plays an important role in the
regulation of cardiovascular system in males. A positive correlation between
circulating Ang-(1-7) concentrations and vascular endothelial function was
reported in healthy men [288]. Also, MasR deficient mice exhibited endothelial
dysfunction and impaired in vitro and in vivo heart function [177]. The effect of
MasR deficiency on BP in male mice seems background specific, in particular,
male mice of C57/BL6 background were reported to be more resistant to MasR
deficiency-associated reductions in endothelial function and elevations in BP
[177, 188]. Similarly, results from the present study demonstrated a reduction in
LV function in MasR deficient mice as indicated by reduced LVEF at baseline.
Moreover, male MasR-/- mice fed standard murine diet exhibited significantly
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lower H/R ratios compared with wild-type littermates, suggesting these mice have
thinner LV walls but larger LV end-diastolic dimension which characterizes the
eccentric hypertrophy of LV. If this cardiac structural change happened early in
life it may predispose MasR-/- mice to cardiac dysfunction and contribute to the
observed reductions in LVEF. While there was no obvious structural change in
MasR+/+ mice after one month HF-feeding, the H/R ratio in MasR-/- mice
increased significantly with HF feeding. Interestingly, HF-fed MasR-/- mice were
able to maintain their low LVEF whereas MasR+/+ mice showed significant
reductions in LVEF after 1 month of HF feeding compared to baseline values. At
first glance, these data suggest a favorable role of MasR deficiency in cardiac
physiology associated with HF feeding; however, this accelerated remodeling in
MasR-/- mice compared to MasR+/+ mice may lead to irreversible structural
changes and cardiac dysfunction with chronic HF feeding. In contrast, HF
feeding-associated reductions in LVEF in MasR+/+ mice appear to be reversible,
since administration of Ang-(1-7) restored LVEF in HF-fed MasR+/+ mice.
Obesity is a risk factor for various heart diseases. Obesity produces
hemodynamic changes and alterations in cardiac morphology that predispose
obese people to heart diseases such as heart failure [263]. On the other hand,
numerous studies have demonstrated that obese patients with established heart
failure appear to have better prognosis than leaner counterparts. Studies
investigating obesity effects on cardiac function in animal models generated
mixed results. Moreover, gender differences in obesity-associated changes in
cardiac function are largely unknown since studies almost exclusively focus on
144

males. Results from the present study demonstrate that both chronic HF and LF
feeding lead to significant reductions in LVEF in wild-type obese mice of both
genders. In addition, reductions in LVEF associated with HF feeding tend to be
more pronounced in obese male than female mice. Interestingly, chronic HF
feeding did not result in further reductions in LVEF in MasR-/- mice likely due to
the compensatory remodeling of the LV. Moreover, MasR-/- male mice may have
difficulties compensating to the obesity-induced increases in cardiac demand.
Over time, this would manifest as reduced blood pressure as observed in male
HF-fed MasR deficient mice.
4.4 Study limitations
4.4.1 Limitations of the model of whole-body ACE2 deficiency
ACE2 exhibits wide-spread tissue expression in both humans and
experimental animals. The highest expression is seen in the gastrointestinal
tract, but ACE2 is also expressed in brain, heart, kidney, lungs, and adipose
tissue [66, 67]. In addition, site specific expression of ACE2 has been reported to
exert non-enzymatic functionality which could impact overall health in
experimental animal models. For instance, intestinal expression of ACE2 was
demonstrated to be colocalized with a neutral amino acid (AA) transporter B0AT1,
and deficiency of ACE2 resulted in the loss of B0AT1 in small intestine and
reduced neutral AA absorption [289].
Studies in Aim 1 were designed to test the hypothesis that estrogen
stimulates adipose ACE2 activity and restores protection of Ovx female mice
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from obesity-hypertension. To determine if estrogen stimulation of ACE2 was
specific to adipose tissue, we also examined RAS components in liver and
kidney, as these tissues exhibit high ACE2 expression [67]. Our results suggest
that estrogen has a relatively specific effect to stimulate adipose ACE2, as these
other tissue sources of ACE2 were unaffected by estrogen administration.
However, it is possible that estrogen influences other tissue sources of ACE2.
For example, ACE2 overexpression in brain has been reported to reduce BP in
several experimental models of hypertension [115-117]. In addition, estrogen
action through ERα has been suggested to regulate the brain RAS and contribute
to sex differences in the development of AngII-induced hypertension in mice
[242]. Thus, there is a possibility of estrogen regulation of ACE2 in the brain
contributing to the BP lowering effect observed in the present study. Moreover,
recent studies also suggest that estrogen acting through ERα stimulates ACE2
mRNA expression and production of Ang-(1-7) in human endothelial cells [190].
Limitations related to tissue-specificity of estrogen-stimulation of ACE2 could be
overcome in future studies using mice with adipocyte-specific ACE2 deficiency.
4.4.2 Other technical limitations associated with E2 administration
4.4.2.1

Serum estrogen quantification

In this study, serum E2 concentrations were quantified using a mouse/rat
ELISA Kit from CalBiotech. Although this kit is cited in the literature to be the
most reliable, measured serum E2 concentrations in this study were at the low
end

of

the

kit

sensitivity

range.

We

considered

using

gas

chromatography/tandem mass spectrometry (GC/MSMS) to quantify serum E2,
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which may yield more accurate results. Unfortunately, pilot studies suggest that
this method requires >150 µl of mouse serum, which is prohibitive for quantifying
additional analytes.
4.4.2.2

Lack of ability to quantify both plasma Ang-(1-7) and AngII

concentrations
As ACE2 catabolizes AngII to form Ang-(1-7), quantification of plasma
concentrations of both AngII and Ang-(1-7) would provide a more complete
assessment of the AngII/Ang-(1-7) axis, as well as in relation to ACE2. However,
due to limitations in mouse plasma volume, we either quantified plasma
concentrations of AngII (Aim 1) or plasma concentrations of Ang-(1-7) (Aim 2).
Thus, we were unable to define the relative balance of these important
biologically active angiotensin peptides.
4.4.2.3

Method for E2 delivery

In the present study, E2 was delivered via subcutaneous silastic tubes. While
this method is preferred for its stable, slow release and technical ease, it is
inconvenient in studies requiring long-term drug administration. Since the tubes
need to be replaced every month, 4 replacement surgeries were performed on
each mouse for the 4-month feeding studies, increasing the likelihood for stress
as a variable in experimental outcomes.
4.4.2.4

Lack of E2 effect in male mice
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E2 administration in male mice did not result in increased serum E2
concentrations and had no effect on obesity-hypertension. The lack of increase in
serum E2 concentrations in male obese mice is a limitation of effectiveness of
drug delivery. However, since E2 administration to males is not a marketable
therapeutic option from a translational perspective, we did not pursue additional
methods to optimize E2 delivery in males.
4.4.3 Limitations of the model of whole-body MasR deficiency
Much like ACE2, there is a fairly wide expression of the MasR gene across
tissue types. Early studies reported expression of MasR gene in the brain, trunk,
and visceral yolk sac tissues of mouse fetuses at 11 days of gestation,
suggesting an important role of the MasR gene during development [290].
Notably, MasR deficient mice exhibit impaired cardiac function which seems
consistent across different genetic backgrounds. Moreover, unlike findings from
aged ACE2 deficient mice, which exhibited impaired cardiac function with
advancing age, the cardiac phenotype of MasR deficient mice was present in
neonates [177]. Since cardiac function is a critical determinant of BP,
compromised congenital cardiac function in MasR deficient mice impacts the use
of this model to explore the role of Ang-(1-7)/MasR axis in obesity-hypertension.
The possible effect of MasR deficiency to increase BP may be masked by its
negative effects on heart function, because cardiac dysfunction can lead to
hypotension. Because of this concern, we assessed left ventricular function
longitudinally in the present studies with the hope to better understand the
relationship between BP and cardiac function.
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4.4.4 Limitations of the LF diet used as control
We did not expect to observe reductions in LVEF in LF-fed mice over time.
Since the lack of difference in LVEF between MasR+/+ and MasR-/- mice can’t be
fully explained by either aging or anesthesia, we suggest that it is possible that
both the LF and HF diets have detrimental effects on LV function but likely
through different mechanisms. While the LF diet used in this study is an
appropriate control for HF feeding in regard to the development of obesity and
obesity-hypertension, it may not be an optimal control diet for studies focused on
cardiac function. It has been suggested that the absence or overabundance of
one fuel (fats or carbohydrates) may result in cardiac metabolic toxicity and
contractile dysfunction [265]. Indeed, acute depletion of free fatty acid in heart
failure patients resulted in depressed cardiac work and efficiency [266].
Moreover, high carbohydrate intakes as well as carbohydrates from refined
starches or added sugars have been positively associated with increased risk of
heart diseases [267]. The low fat content (10% kcal from lard and soybean oil)
and high carbohydrate content (70% kcal from sucrose and corn starch) of the LF
diet used in this study may have influenced LVEF over time. Future studies
should investigate different control diets for obesity-related studies to address
this question.
4.4.5 Other technical limitations in MasR deficiency studies
Along with longitudinal assessment of LV function, it would be optimal to
assess BP longitudinally during the course of HF feeding. Unfortunately, tail cuff
platforms do not provide accurate measurement of BP in obese mice, and are
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not dynamic in nature if BP is the primary study outcome. Moreover, in our
experience, carotid artery catheters do not remain patent for BP monitoring
longer than 1.5 months. Additionally, tail cuff platforms are stressful on the mice
during acclimation and measurement. Thus, BP was recorded at the study
endpoint only using the sensitive and previously published method of
raiotelemetry. Monitoring the changes in BP through the duration of the HF diet
challenge correlated with changes in LV function would be useful in determining
the 1) effect of comprised cardiac function in MasR deficient mice on the
development of obesity-hypertension and 2) the effect of changing cardiac
function with obesity in wild-type mice on the development of obesityhypertension.
4.5 Clinical significance
Despite the therapeutic advances in treating hypertension, the rate of
controlled hypertension is still low.

According to recent data from the CDC,

approximately 50% of hypertensive patients have controlled blood pressure
within the target range. Moreover, data form several hypertension trials indicate
that a large proportion of hypertensive patients require two or even three
antihypertensive medications to achieve target BPs [291]. Since currently
available antihypertensive therapies are not sufficiently controlling BP in most
patients, there is a need for novel therapies. With regard to obesity-hypertension,
there are few human studies comparing the effect of different antihypertensive
drugs in hypertensive patients with obesity, much less in males compared to
females. It has been suggested that use of AT1R antagonists (ARBs), compared
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to diuretics, may provide the additional benefit of improving insulin sensitivity and
suppressing sympathetic nerve activity in addition to lowering BP lowering in
obese hypertensive patients [292, 293]. In another study, the renin inhibitor,
aliskiren, was more effective in obese hypertensive patients that were resistant to
diuretics compared with calcium channel blocker or ARBs [294]. However, there
are no recommendations for preferential use of one drug over another in treating
obesity-hypertension.
The use of antihypertensive drugs in men versus women is even more
complicated. According to data from NHANES 1999-2004, women, compared to
men, were more likely to receive diuretics (31.6% vs. 22.3%) and ARBs (11.3%
vs. 8.7%). Among treated hypertensive patients, fewer women are taking three or
more antihypertensive drugs than men, and the control rate is lower in women
(44.8%) compared to men (51.1%) [295]. In studies looking at antihypertensive
drug therapy internationally in 26 countries, the overall BP control rate was
reported to be lower in women (30.6%) than men (33.6%). Women received
more frequently thiazides and beta-blockers and less frequently ACEi as
monotherapy. In patients receiving dual therapies, the BP control rates were
always higher in men than women in almost all combined regimes except in two
that contained ARBs [296]. For unknown reasons, antihypertensive therapy is
less effective in females, suggesting that additional efforts should be made to
improve BP management in women. Studies have suggested that beneficial
effects of ARBs may partially be attributed to an ACE2 mechanism, since
blockade of the AT1R increases the availability of AngII as a substrate for ACE2151

mediated production of Ang-(1-7). The fact that BP control rates were relatively
higher in women receiving ARBs with dual-therapy BP management supports a
role for a stimulated ACE2/Ang-(1-7)/MasR pathway as an antihypertensive
mechanism.
Studies in this dissertation suggest that the ACE2/Ang-(1-7)/MasR axis is
critical in females for protection against obesity-hypertension. While many drugs
have been developed to inhibit the classical RAS arm to ultimately prevent the
action of AngII acting on the AT1R, no pharmacologic therapies targeting the
counter-regulatory arm of the RAS currently exist. One reason is that it may be
more difficult to activate rather than inhibit a pathway from the drug development
perspective. Results from the present study suggest that estrogen alone may
afford protection from obesity-hypertension through stimulation of ACE2 in
postmenopausal women, which is an interesting mechanism that has clinical
implications worth further investigation. Similarly, studies suggest beneficial
effects of ACE2 activation as well as Ang-(1-7) administration in animal models
of hypertension. Thus, upregulation of the ACE2/Ang-(1-7)/MasR axis may be
considered as potential therapy for hypertension in women.
4.6 Future directions
In order to fully elucidate whether the effects of estrogen to reduce plasma
AngII concentrations and lower BP are specific to adipose ACE2, these results
suggest that studies should be performed in mice with adipocyte-specific ACE2
deficiency. Studies in our lab suggest both increased AngII and decreased Ang-
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(1-7) contributes to the development of obesity-hypertension in Ovx females;
therefore, it would be of interest to compare the effect of ARBs and Ang-(1-7) to
that of estrogen on the protection from development of obesity-hypertension in
Ovx females. In addition, results from studies in Aim 1 suggest a protective role
for estrogen in Ovx female mice; however, it is not clear whether estrogen has
the ability to reverse the obesity-hypertensive phenotype of Ovx female mice,
which would have more implication in a clinical setting. Similarly, to define the
role of MasR deficiency in the development of obesity-hypertension without
influence from congenital cardiac complications, tissue specific MasR deficiency
is needed for future studies.
4.7 Concluding Remarks
In conclusion, findings of this dissertation demonstrate a pivotal role of
ACE2/Ang-(1-7)/MasR axis in the development of obesity-induced hypertension
in female mice. In addition, results suggest estrogen alone may afford protection
of obesity-induced hypertension in postmenopausal women through stimulation
of adipose ACE2.
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